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Malaria disease poses a serious global health burden as recent reports have indicated that nearly 
half of the world’s population is at risk (WHO 2008). The World Health Organization (WHO) 
Expert Consultative Team has reported that 90% of all malaria deaths occur in Sub Saharan 
Africa. (WHO, 2008). Despite the numerous global efforts to control and manage the disease, 
through various ways, use of chemotherapeutic agents continues to be the major intervention 
strategy in the control of malaria. The WHO recommended use of Artermisinin combination 
therapy (ACT) has been hampered by an imbalance between demand and supply in the poor 
socioeconomically challenged rural populations of Sub Saharan Africa, the epicenter of malaria 
infection. Chloroquine (CHQ), therefore, continues to be used in most malaria endemic areas in 
developing countries despite development of P. falciparum resistance to the drug (WHO, 2006). 
Oral administration is the major delivery route for CHQ. However, CHQ is a bitter drug, with an 
inconvenient dosing schedule leading to incomplete courses of therapy by most malaria patients. 
Oral CHQ administration is also associated with adverse effects in various organ systems 
resulting from deposition of CHQ in these organs to elicit impairment of glucose homeostasis, 
renal and cardiovascular function. Alternative methods of CHQ administration such as 
transdermal delivery have, therefore, been suggested, in an effort not only to avoid the bitter 
taste, but also to modify the dosing schedule, which may improve patient comfort and 
compliance. Transdermal delivery of CHQ via an amidated matrix patch, which is envisaged to 
ensure a slow, controlled and sustained release of therapeutic concentrations of CHQ, may 
circumvent the previously reported adverse effects of oral CHQ. It is against this background 
that the current study compared the effects of transdermal CHQ patch and oral chloroquine in the 
management of malaria as assessed by the ability to clear parasites of P. berghei infected rats. 
The other aims were to investigate and distinguish between the patho physiological effects of 
malaria and CHQ treatments on blood glucose and plasma insulin concentration, renal and 




To investigate and distinguish between the pathophysiological effects malaria infection and CHQ 
treatments on blood glucose homeostasis, renal and cardiovascular function markers, separate 
groups of non infected and P. berghei infected male Sprague Dawley rats (90g-150g) were used. 
The animals were treated twice daily with oral CHQ (60mg/kg) and a once off transdermal 
delivery of CHQ via topical application of pectin CHQ matrix patch (53mg/kg) in a 21 day study 
divided into pre treatment, (days 0-7) treatment (days 8-12) and post treatment (days 13-21) 
periods. The animals were housed individually in metabolic cages for the duration of the study. 
Treatment was for 5 consecutive days. Measurements of body weight, food and water intake, 
mean arterial pressure (MAP), blood glucose concentration, % parasitaemia, haematocrit, and 24 
hour urine volume, Na+, K+, urea and creatinine outputs were done every day during the 
treatment period, and every third day during the pre and post treatment periods. Separate groups 
of non fasted conscious animals (n=6) were sacrificed on days 0, 7, 8, 9, 10, 12, 14 and 21, at 24 
hours after the last treatment for oral CHQ administration and after a once off patch application 
on the first day of treatment. The plasma obtained was assayed for plasma insulin, lipid profile 
parameters and plasma Na+, K+, urea and creatinine. The harvested liver and gastrocnemius 
muscle were used for determination of glycogen concentration.  
 
The current study has demonstrated the sustained controlled release of CHQ from the pectin 
matrix patch, demonstrating the therapeutic ability to clear P. berghei malaria parasites from 
systemic circulation. Malaria infection and oral CHQ treatment exhibited blood glucose lowering 
effects which were circumvented by topical application of the pectin CHQ matrix patch.  
Oral CHQ elevated hepatic glycogen concentration through mechanisms that are still to be 
elucidated. Topical application of CHQ via pectin matrix patch did not alter hepatic and 
gastrocnemius muscle glycogen concentrations. Malaria infection and oral CHQ delivery 
reduced food intake, water intake and % body weight changes of the animals as well as inducing 
natriuresis, reduced urine output and increased urinary creatinine outputs. Malaria infection was 
also shown to elicit hyperkalaemia and kaliuresis in experimental animals. Hypotensive effects 
of malaria infection and oral CHQ delivery were also demonstrated in the current study. Malaria 
infection and oral CHQ delivery elevated plasma total cholesterol and LDL-c as well as 
reduction in the cardio protective particle, plasma HDL-c, concentrations. Topically delivered 
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CHQ via pectin CHQ matrix patch did not evoke any such alterations, suggestive of its ability to 
circumvent the observed adverse effects of oral CHQ delivery due to sustained, controlled 
release of therapeutic concentrations of CHQ from the transdermal formulation.  
To the best of our knowledge, the results of the present study provides the first evidence of the 
release of therapeautic CHQ concentrations from pectin CHQ matrix patch that cleared the 
malaria parasites from systemic circulation as well as demonstrating the ability of the 
transdermal formulation to circumvent the adverse effects of oral CHQ delivery in glucose 
homeostasis, renal and cardiovascular function markers. This is clinically relevant as it provides 
a feasible and novel alternative method of CHQ delivery that could play a major role in the 
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1.0 Background       
Malaria is an acute infectious disease caused by Plasmodium parasites and spread by the female 
anopheles mosquito (WHO 2008, Tuteja 2007). The disease poses a serious global health burden 
as recent reports have indicated that nearly half of the world’s population is at risk (WHO 2008). 
The World Health Organization (WHO) Expert Consultative Team has further reported that 200-
300 million people suffer from acute malaria with a total of 0.5-2.5 million people dying from 
the disease each year. Sub Saharan Africa is the worst affected by the disease, since 90% of all 
malaria deaths occur in this region (WHO, 2008). It is noteworthy that despite the numerous 
global efforts to control and manage the disease through good surveillance and high intervention 
coverage, malaria remains the third ranked cause of death among the major infectious diseases 
such as Acquired Immuno Deficiency Syndrome (AIDS) and tuberculosis (TB) (Snow, 2003). 
Early treatment using effective antimalarial drugs, therefore, remains the major intervention 
strategy in the control of malaria. However, development of P. falciparum resistance to the 
major, previously effective malaria drugs has hampered global malaria control efforts, 
demonstrating a need for new therapeutic agents. WHO has recommended use of artemisinin 
combined therapy (ACT), which have, however, proved to be costly and inaccessible to the 
majority of people in developing countries (Yeung et al., 2004; WHO, 2006; Whitty et al., 2008; 
WHO, 2008). Chloroquine (CHQ), therefore, continues to be used in most malaria endemic areas 
in developing countries despite development of P. falciparum resistance to the drug (WHO, 
2006). Oral administration is the major delivery route for CHQ. The dosing schedule of 4 tablets 
at presentation, 2 tablets 6-8 hours later and 2 tablets on the next two consecutive days is, 
however, relatively inconvenient (Musabayane et al., 2003). Additionally, CHQ’s bitterness 
elicits non-compliance in majority of patients resulting in non completion of the treatment 
regimen, which has been suggested to be one of the major causes of rapid development of P. 
falciparum resistance to the drug (WHO, 2006). Following the high, initial CHQ doses required 
for oral delivery, the drug deposits in all epithelial cells of the body to elicit adverse effects in 
various organ systems (Gustafsson et al., 1983). Current studies have shown that orally delivered 
CHQ may elicit adverse effects on glucose homeostasis (Smith et al., 1987, Asamoah et al., 
2 
 
1990), renal (Musabayane et al., 1994, Musabayane et al., 1999) and cardiovascular functions 
(Sofola et al., 1981, Mubagwa and Adler, 1988, Sofola, 2008). Alternative methods of CHQ 
administration such as transdermal delivery have, therefore, been suggested, in an effort not only 
to avoid the bitter taste, but also to modify the dosing schedule, which may improve patient 
comfort and compliance (Musabayane et al., 2003). Transdermal delivery of CHQ via an 
amidated matrix patch, which is envisaged to ensure a slow, controlled and sustained release of 
therapeutic concentrations of CHQ, may circumvent the previously reported adverse effects of 
oral CHQ. It is against this background that the current study investigated and distinguished 
between the pathophysiological effects of malaria infection and CHQ treatments on glucose 
homeostasis, renal and cardiovascular function.  
The subsequent sections in this chapter will describe various aspects of malaria disease, control 
and management using malaria drug armoury. A review of CHQ as an antimalarial drug and 
associated adverse effects oral CHQ delivery will also be highlighted. Various transdermal 




1.1. Malaria infection         
The four identified Plasmodium species that cause human malaria are, Plasmodium vivax, 
Plasmodium ovale, Plasmodium falciparum, and Plasmodium malariae. Plasmodium falciparum 
is the most common in Sub Saharan Africa while Plasmodium malariae is sporadic worldwide 
(Snow, 2003, White et al., 1999, Tuteja, 2007). Occasional infections with monkey malaria 
parasites, such as Plasmodium knowlesi may also occur (Tuteja, 2007). Generally, Plasmodium 
berghei, that only infects rodents, is used for experimental purposes to study human malaria, as it 
is not hazardous to humans (Janse and Waters, 1995).  P. vivax and P. ovale infect only young 
red blood cells, P. malariae infects only aging cells while P. falciparum invades erythrocytes at 
any age (WHO 2006). The ability of P. falciparum to invade erythrocytes of any age explains the 
heavy parasitaemia generally observed in P. falciparum infection. Plasmodium infections lead to 
hemodynamic, immunologic, and metabolic pathogenic features which are initiated by 
parasitized red blood cells (Barsoum, 2000). Other less common modes of malaria transmission 
include inoculation of blood from an infected person to a healthy person, such as in blood 
transfusion (WHO 2003). The Plasmodium parasites have a similar, but complex life cycle 
discussed in the next section.  
 
1.1.1. Life cycle and pathogenesis of Plasmodium falciparum    
The life cycle of Plasmodium occurs in a host (man) and a vector (mosquito). Malaria is acquired 
through a bite of an infected female Anopheles mosquito, which injects the sporozoites into the 
host’s dermis. The sporozoites are then carried in the blood stream to the hepatocytes in the liver. 
They mature to tissue schizonts, which later releases merozoites into liver sinusoids. This is the 
extra-erythrocytic cycle (Figure 1). 
The erythrocytic cycle starts when the mature tissue schizonts invade the red blood cells (RBC) 
leading to the formation of ring forms or trophozoites.  However, in case of P. vivax and P. 
ovale, some sporozoites may go into hibernation, (the cryptobiotic phase), giving rise to 
hypnozoites. The hypnozoites can lie dormant for months or years and upon reactivation they 
cause clinical relapse (Clark and Schofield, 2000, Mackintosh et al., 2004, Tuteja, 2007). The 
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trophozoites formed subsequently develop into schizonts that later release a new generation of 
merozoites. The parasitized red blood cells eventually rupture to release a new generation of 
merozoites into the blood stream to repeat the same cycle. The sexual cycle in the vector is 
completed by differentiation of some merozoites into male and female gametocytes (Clark and 
Schofield, 2000, Mackintosh et al., 2004). The malaria parasite has been shown to have complex 
metabolic processes such as utilization of amino acids derived from haemoglobin and 
detoxification of haeme. The enzyme plasmodium aldolase has been identified as one of the 
enzymes of parasite anaerobic glycolysis (Clark and Cowden, 2003). Reports indicate that the 
parasites increase the permeability of red blood cell to acquire nutrients, yet maintaining the red 
blood cell structure intact for at least 48 hours (Clark and Schofield, 2000, Mackintosh et al., 
2004). The parasite ingests haemoglobin from RBCs to form a food vacuole where haemoglobin 
is degraded, releasing haem moeity. The toxic haeme is in turn detoxified by haeme polymerase 
and sequestrated as haemozoin (malaria pigment). Many of the antimalarial drugs act by 
inhibiting haeme polymerase thereby causing accumulation of toxic haeme moeity (Clark and 
Schofield, 2000, Mackintosh et al., 2004). The basic life cycle of all the Plasmodium species is 





Figure 1: Illustration of the life cycle of malaria parasites of Plasmodium spp 
 
The life cycle of the plasmodium parasite is indicative of the general observation that malaria is a 
complex multisystem disorder, characterized by a wide range of clinical outcomes such as fever 
and anaemia (Clark and Cowden 2003). The infection of RBCs with malaria parasite is 
associated with changes in their adhesion properties resulting in RBC deformability which is 
associated with increased mechanical fragility (Kaul et al., 1991; Kaul et al., 1994; Clark and 

























erythrocytes, blood platelets, and the capillary endothelium, leading to the formation of 
intravascular rosettes and clumps that may impede microcirculation (Dondorp et al., 2000, 
Dondorp et al., 2004). Impediment of microcirculation may lead to hypoxia, reduced metabolite 
exchange and the release of inflammatory mediators (Clark and Cowden 2003). 
 
A general imbalance in the secretion of pro and anti-inflammatory cytokines in response to 
malaria induced hypoxia has been reported (Jason et al., 2001; Clark and Cowden, 2003). 
Elevated plasma concentrations of pro inflammatory cytokines such as TNF-α and IFN-γ and a 
reduction of anti inflammatory cytokines such as IL-10 may be responsible for 
pathophysiological and clinical outcomes of malaria. Pro inflammatory cytokines are secreted 
following release of parasite antigens during the bursting of pRBCs (Clark and Cowden, 2003).  
Generally, episodic development of fever in malaria infection coincides with episodic bursting of 
pRBCs to release merozoites during schizogony. However, the fever associated with malaria 
patients on CHQ treatment is non specific. We speculated that the fever may be caused by the 
parasite, CHQ or both as literature reports remain unclear to date.  
 
Development of anaemia is another non specific clinical outcome of malaria (Bjorkman, 2002). 
The pathophysiology of malarial anaemia is relatively multifactorial and complex (Menendez 
2000). Current literature evidence has shown that anaemia may result from pathophysiological 
mechanisms described below. Increased RBC destruction may result from rupture of parasitized 
red blood cells (pRBC), which occurs in direct proportion to the percentage parasitaemia and 
schizontaemia (Bjorkman, 2002; Clark and Cowden 2003). Phagocytosis of pRBC also causes a 
reduction of RBCs in malaria infected patients. The process of phagocytosis is mediated by 
proliferating and hyperactive macrophages in the reticuloendothelial system (Menendez 2000). 
Unparasitized RBCs are also prone to phagocytosis as a result of reduced deformability as well 
as due to the presence of membrane binding parasite antigens. (Menendez 2000; Ghosh and 
Ghosh, 2007). The spleen also increases the clearance of both parasitized and non infected 
erythrocytes (Dondorp et al., 1999). Inflammatory processes may cause decreased RBC 
production due to growth suppression of early precursors of RBC production (Dormer et al., 
1983; Menendez 2000; Clark and Cowden 2003). Erythropoietin synthesis has also been 
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demonstrated to be suppressed in malaria (Yap and Stevenson, 1994; El Hassan et al., 1997; 
Dondorp et al., 1999; Chang et al., 2004; Fendel et al., 2010). Dyserythropoiesis has been 
implicated in decreasing RBC production in falciparum malaria as well as eliciting an imbalance 
of cytokines. (Ghosh and Ghosh, 2007). Excess of tumor necrosis factor alpha (TNF-α), 
interferon gamma (IFN-γ) and nitric oxide (NO) and reduced plasma interleukin (IL-10) have 
also been associated with excessive RBC destruction in malaria (Menendez 2000; Clark and 
Cowden 2003; Ghosh and Ghosh, 2007). 
 
It is speculated that the quinoline ring of quinine related antimalarial drugs may act as a hapten 
combining with specific RBC proteins to become antigenic thereby leading to RBC destruction 
(Clark and Cowden, 2003). The causes of anaemia associated with malaria patients on CHQ 
treatment are, therefore, still unclear, indicating that there is need to investigate and distinguish 
between the pathophysiological effects of malaria and CHQ treatment. Haematocrit 
measurement is an index of RBC volume blood. Accurate diagnosis of malaria is pivotal in the 
control of the global burden of malaria as discussed in the next section. 
 
1.1.2. Diagnosis of malaria        
Diagnosis of malaria is based on clinical criteria (clinical diagnosis) supplemented by the 
detection of the parasites in the blood (parasitological or confirmatory diagnosis) (WHO, 2006; 
WHO 2008). Prompt and accurate diagnosis of malaria is part of effective disease management, 
whose implementation may effectively help to reduce unnecessary use of antimalarials (WHO, 
2006). Confirmatory diagnosis can be done either by the traditional peripheral smear 
examination using light microscopy and/or rapid diagnostic tests(RDTs) (Rubio et al., 2001, 
Williams et al., 2008). This improves the specificity of malaria diagnosis thereby reducing drug 
wastage through unnecessary treatment of patients without parasitaemia. RTDs are more useful 
in the field when light microscopy is unavailable or during times of an epidemic when diagnosis 
of all cases using light microscopy is impractical. The use of RTDs is, however, limited by high 
cost, variable sensitivity and specificity, as well as vulnerability to temperature changes and 
humidity (WHO, 2006; WHO 2008). WHO, 2008 has previously reported that reduction of 
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transmission of the malaria parasite is still possible (WHO, 2008). Various ways of controlling 
malaria transmission are mentioned in the next section. 
1.1.3. Control of malaria transmission       
Malaria control involves three living beings, man (the host), Plasmodium species (the agent), and 
anopheles mosquito (the vector). Control of malaria transmission may occur through ways that 
ensure reduced exposure to infected malaria parasites in order to reduce chances of infection 
(Muturi et al., 2008; WHO 2008). Another level of malaria transmission control involves 
methods that promote inhibition of vector proliferation and multiplication. Prevention of 
individual infection requires dedicated and continuous efforts. Every individual living in or 
visiting malarias areas should adopt personal protection measures against mosquito bites (WHO 
2006; WHO 2008). These protective measures include closing of windows and doors, screening 
of windows, use of mosquito repellant creams, lotions, coils and mats as well as mandatory use 
of mosquito nets, preferably insecticide treated bed nets. Such travelers should take 
chemoprophylaxis of anti malarial drugs (WHO 2006; WHO 2008). Mosquito control measures 
such as source reduction, use of larvicides (chemical, biological) and use of adult insecticides 
may also be helpful (WHO 2006; WHO 2008). In cases where transmission cannot be avoided 
altogether, prompt administration of effective antimalarial drugs to infected individuals is 
another level of malaria transmission control (White, 2008; WHO 2008). The administration of 
effective treatment is indispensable to averting progression of uncomplicated malaria into severe 
complicated malaria (WHO 2006; Day and Dondorp, 2007). The major limitation to the control 
of malaria transmission through administration of effective antimalarial drugs in Sub-Saharan 
Africa is that medical facilities are limited, poorly equipped and poorly funded, despite being the 
epicentre of malaria infection (WHO 2006; WHO 2008). 
1.2 Drug intervention 
Intensification of good surveillance and high intervention coverage in some African countries 
has made the possible elimination of malaria a realistic goal. The studies done by a WHO Expert 
Consultative Team reported a decline in malaria cases and deaths by 50%. (WHO, 2008). 
However, 90% of all the malaria cases and deaths that occur to date due to malaria are in Sub 
Saharan Africa (WHO 2008). The current global morbidity and mortality due to malaria can be 
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reduced by access to early and effective treatment (WHO 2006; WHO 2008). Multidrug 
resistance of the commonly used anti-malarial agents such as CHQ and 
sulphadoxine/pyrimethamine (SP) combination has been reported in most parts of the world 
(WHO 2006; 2008). Thus, monotherapy or some of the available combination therapies for 
malaria are either ineffective or less effective (WHO, 2006). Combination antimalarial drug 
therapy, the simultaneous use of two or more blood schizontocidal drugs with independent 
modes of action and different biochemical targets in the parasite, is widely advocated in malaria 
treatment (WHO, 2006). Treatment of malaria involves administration of a blood schizonticidal 
and gametocytocidal for preventing relapse and transmission, respectively (WHO 2006). The 
concept of combination therapy is based on synergistic or additive potential of two or more drugs 
(Olliaro and Taylor, 2004). Anti-malarial drug combinations can increase efficacy and shorten 
duration of treatment thereby increasing compliance. This will, therefore, decrease the risk of 
resistant parasites (WHO, 2006; WHO 2008). The major general limitation of drug combination 
therapy, however, is the increased cost of the drug. The next section will briefly discuss the 
currently available antimalarial drug amoury. 
 
1.2.1 Artermisinin derivatives 
The medicinal Chinese herb, Artemisinia annua is the source of artermisinins, which are 
currently considered to be the cornerstone of malaria treatment (WHO, 2006). Artemisinin drugs 
have a rapid onset of action and are considered to be highly potent. The WHO Expert 
Consultative Group has advocated for the use of artemisinins in combination therapy to reduce 
development of malaria parasite resistance to the drugs that may occur if they are used as 
monotherapy (WHO, 2006). The currently available ACTs include artemether-lumefantrine 
(coartem), artersunate-mefloquine and artesunate-amodiaquine. The mode of action of 
arteminisins is through the generation of free radicals which cause haemolysis and lysis of 
infected cells. All the artemisinin derivatives possess both schizontociadal and gametocytocidal 
activities, giving artermisinin drugs the ability to clear the malaria parasite infection as well as to 
reduce malaria transmission by reducing gametocyte carriage rates (Nosten and White, 2007, 
Ogbonna and Uneke, 2008). The major limitations of the drugs include, an imbalance that 
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currently exists between demand and supply, comparatively high cost, dosing complexity and 
basic lack of clinical experience (Bloland, 2003). Literature evidence currently shows that there 
is no existence of any serious side effects to ACTs in humans. However, toxicity in the nervous 
system has been reported in animal studies (Greenwood et al., 2008; Kongpatanakul et al., 2009).  
1.2.2 Quinine related drugs 
The presence of the quinoline ring, characterizes all drugs that are classified as quinine related 
drugs. Such drugs include quinine, mefloquine, primaquine and chloroquine. Each of these drugs 
will be discussed briefly, in the next section, except chloroquine, which will be discussed in a 
later section. 
1.2.2.1 Quinine 
The shrubs of various species of Rubiacheous genera, Cinchona and Remijia are the sources of 
quinine, which was the first successful antimalarial drug. Quinine has both schizontocidal and 
gametocytocidal activities against P. falciparum, P. vivax and P. malariae (Barrenes 1996; 
WHO, 2006). Quinine has, however been shown to be associated with a wide range of side 
effects collectively known as cinchonism (WHO, 2006). Cinchonism refers to a collection of 
symptoms such as tinnitus, deafness, nausea, vomiting and vasodilation, which manifests when 
there is quinine overdose (Bateman et al., 1985). The development of such side effects has 
generally resulted in patient non compliance.  
1.2.2.2 Mefloquine 
The drug has schizontocidal activity, but has no effect on the hepatic stage of the malaria 
parasites (WHO 2006). Mefloquine has a long half life, which has led to contra indications in 
malaria endemic areas (WHO, 2006). Resistance of Plasmodium parasites to mefloquine has 
been reported, thereby promoting the use of the drug in combination therapy (WHO, 2006; WHO 
2008). Winstanley, 1996 reported an association of neuropsychiatric adverse events with 





Malaria relapses that are mainly due to the pre-erythrocytic liver latent forms of P. vivax and P 
ovale can be eliminated using primaquine, an 8 aminoquinoline drug (Jeans and Heard, 1999, 
WHO 2006). Primaquine possesses both blood and tissue schizontocidal and gametocytocidal 
activities (Butcher, 1997; WHO 2006; WHO 2008). The drug’s major limitation is the 
precipitation of haemolytic anaemia in glucose-6-phosphate dehydrogenase (G-6-P) deficient 
patients (Jeans and Heard, 1999). 
1.2.2.4 Chloroquine 
CHQ, a diprotic compound possesses both blood schizonticidal and gametocytocidal activities 
against CHQ sensitive Plasmodium parasites (Butcher, 1997; WHO, 2006). CHQ mode of action 
and effects on various organ systems will be discussed in a later section. 
1.2.3. Antifolates 
Inhibition of folate metabolism of P. falciparum is the target site for antifolate drugs such as 
pyrimethamine, sulphadoxine and proguanil (Bzik et al., 1987). Antifolate drugs inhibit key 
enzymes, dehydrofolate reductase (DHFR) and dehydropteroate synthase (DHPS) in the 
parasite’s folate metabolic pathway (REF). Interference with these enzymes compromises the 
survival of the malaria parasite. Antifolates, targeting different enzymes in the folate patway 
have been used in combination therapy, such as the pyrimethamine/sulphadoxine combination. 
The major limitation of the drug combination is the development of P. falciparum resistance to 
the drug (Nwanyanwu et al., 1996). Pyrimethamine interferes with DHFR while sulphadoxine 
has been shown to interfere with DHPS enzyme activities, respectively. Proguanil, which is used 
in malaria prophylaxis, reportedly inhibits the DHFR as the drug’s mode of action (Mulenga et 
al., 2006). However, further development of proguanil has been hampered by development of P. 





1.2.4 New antimalarial drugs 
Due to the escalating costs of new drug developments, the modifications in the structure of 
existing antimalarial drugs has been the common focus in an effort to introduce new antimalarial 
drugs. Another strategy may be the reformulation of existing drugs. Combination of existing 
antimalarial drugs may also be useful (Fivelman et al., 1999; Biagini et al., 2003; Kremsner and 
Krishna, 2004; Lederman et al., 2006; WHO, 2006; Deen et al., 2008; WHO, 2008). These 
strategies are exemplified by the artemether/lumefantrine combination as well as 
dihydroartemisinin/piperaquine combination (WHO, 2006; WHO, 2008). In each case, a fast 
acting blood schizonticidal drug with gamecytocidal activities is combined with a slow acting 
drug that will clear the parasites slowly in order to avoid recrudescence (WHO, 2006; WHO, 
2008) 
 
1.2.5 Optimisation of therapy 
Amtimalarial drug therapy may be optimised by the use of analogues of existing traditional 
antimalarial agents. The strategy has been very successful in quinine related drugs, where it led 
to the introduction of CHQ, primaquine and mefloquine based on the chemical modification of 
quinine (Winstanley, 2000; WHO, 2006). Antimalarial drug therapy may also be optimized by 
using the traditional, currently available antimalaria agents as drug combinations. One such 
combination is amodiaquine/ sulphadoxine/pyrimethamine combination (WHO, 2006). The use 
of natural plant products may also be an important adjunct in the treatment of malaria. Indeed 
many successful drugs to treat various ailments have been extracted from plants. There are, 
therefore, many plant based products that are currently being evaluated as potential antimalarial 
treatment options. However, they will not be reviewed in this study, as they are outside our 
scope.  
As previously mentioned, CHQ continues to be a drug of choice in Sub Saharan Africa due to its 
wide availability and accessibility despite reported development of parasite resistance to this 
drug. As such, the next section comprehensively discusses the structure, mode of action and 
delivery routes that are employed for this drug. 
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1 3 Chloroquine         
CHQ continues to be the major chemotherapeautic agent used in the treatment and prophylaxis 
of malaria in most malaria endemic tropical countries (WHO 2006; WHO 2008). This is despite 
the worldwide emergence of falciparun resistance to CHQ treatment which has forced the 
majority of African countries to deploy other available drugs as their first line of therapy (White 
et al., 1999, Molyneux et al., 1999, Baird, 2000). Various factors such as inadequate dosing, 
incomplete courses of therapy, indiscriminate and inappropriate use, and reliance on less 
effective medications were the major contributors to the development of falciparum resistance to 
CHQ (Karbwang and Harinasuta, 1992, Bloland et al., 1993). However, in Sub Saharan Africa, 
the alternative, ACT based drug combinations are generally inaccessible, hence the continued 
use of CHQ (WHO 2008). CHQ’s affordability, easy administration, wide availability and rapid 
onset of action has potentiated the drug’s continued use (WHO 2006; WHO 2008). Current 
literature evidence indicates that CHQ is not only used to treat malaria, but other disease 
conditions such as systemic erythomatosus (SLE) and rheumatoid arthritis (RA). The 
lysosomotropic properties of CHQ have enabled the drug to assume such a plethora of uses. 
 
1 3.1 Absorption, metabolism and excretion     
Following oral administration, maximum plasma concentrations of CHQ are attained after 1-4 
hours, which is indicative of the drug’s rapid absorption (Adelusi et al., 1982; Gustafsson et al., 
1983, Walker et al., 1983, White, 1992; Augustijns and Verbeke, 1993, Vries et al., 1994). CHQ 
has the ability to bind avidly to different epithelial cells and body tissues, attributed to the drug’s 
large volume of distribution in the body. The drug has a long elimination half life which varies 
between plasma and tissues (McChesney et al., 1967, Adelusi and Salako, 1982, Wetstein et al., 
1995; Ahmed et al., 2003a). Gene mutations may occur in the major CHQ transporter, PfCRT, 
results in reduced CHQ uptake by RBCs in CHQ resistant strains thereby limiting the 
effectiveness of the drug (Warhurst, 2001). About 70% of CHQ ingested dose is excreted 
unchanged in the urine (Pussard and Verdier, 1994). Current literature evidence has shown that 
the cytochrome P- 450 (CYP) isoform enzymes are involved in CHQ metabolism in humans 
(Projean et al., 2003) 
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1.3.2 Mode of action         
The mechanism of action of CHQ is still not completely understood. (Raynes, 1999).  Yayon and 
Ginsburg, 1983 postulated that CHQ may interfere with the function of the food vacuoles in the 
mature stages of the erythrocytic parasite (Yayon and Ginsburg, 1983). Based on the physico 
chemical properties, CHQ rapidly accumulates within the acidic food vacuole of the parasites to 
exert therapeutic effects (Yayon et al., 1985; Fitch and Russell, 2006). The food vacuole is the 
site of haemoglobin breakdown, to amino acids that nourish the parasite. The by-products of 
haemoglobin breakdown are the toxic haem moieties, also referred to as ferriptoroporphyrin IX 
(FP). FP has been shown to be toxic to RBC membranes and the malaria parasite (Slater et al., 
1991, Slater and Cerami, 1992; Sullivan et al., 1996; Bray et al., 1998; Bray et al., 1999; Fitch 
and Russell, 2006). However, the parasite has the ability to detoxify haematin into non toxic, 
insoluble and inert haemozoin through unclear mechanisms. CHQ exerts antimalarial activity by 
interfering with the process of haem detoxification (Fitch and Russell, 2006).  The drug binds 
with a high affinity to haematin, inhibiting its sequestration into haemozoin (Slater, 1993; Egan 
et al., 1994; Francis et al., 1997; Bray et al., 1998; Foley and Tilley, 1998; Bray et al., 1999). The 
result is the generation of toxic CHQ-haem complexes as well as accumulation of free haem 
moieties within the parasite’s food vacuole (Pandey et al., 2001). The accumulation of such 
moieties is associated with RBC lyses and depressed activity of key enzymes the parasite 
requires for metabolic pathways.  
 
Based on the pharmacokinetic properties of CHQ and the drug’s ability to bind to all epithelial 
cells, we speculated that the initial high oral doses of CHQ could be toxic to organ systems. On 
the other hand, the pathogenesis of malaria may also exert pathophysiological effects to organ 
systems. Currently, there is no literature evidence that distinguishes between the 
pathophysiological effects of malaria and CHQ in malaria patients. The next section discusses 




1.4 Impaired glucose homeostasis       
The pathogenesis and metabolic perturbations of malaria show that the malaria parasite and 
associated fever influences glucose homeostasis of the human host. The parasite heavily and 
completely depends on the host for all its energy requirements, which impact negatively on the 
host’s energy stores (Phillips 1989). The overall effect may be an imbalance between the host’s 
energy demands and supply which may precipitate hypoglycaemia in patients with glucose-
insulin mismatching (Phillips 1989). On the other hand, CHQ has also been shown to affect 
glucose homeostasis through its effects on insulin secretion and breakdown of the activated 
hormone (Knutson, Ronnett and Lane, 1985; Phillips 1986; Davis, 1997; Jarzyna, Kiersztan, 
Lisowa and Brya, 2001). We speculated that, such effects on blood glucose and plasma insulin 
concentrations could affect glycogen stores, in the muscle and liver of the host cell. The 
following section will discuss the independent effects of malaria and CHQ on glucose 
homeostasis. 
 
1.4.1 Effects of malaria on glucose homeostasis  
Consumption of host glucose to meet the parasite’s energy demands may precipitate 
hypoglycaemia through varied mechanisms. One such proposed mechanism is through depletion 
of vital gluconeogenic substrates such as thiamine (Krishna et al., 1999). Thiamine depletion is 
usually preceded by increased serum transketolase activity in patients with falciparum malaria in 
response to increased demand for parasite’s glycolytic pathway (Krishna et al., 1999). Thiamine 
depletion has also been associated with a depression of the host’s aerobic glycolysis, resulting in 
increased anaerobic glycolysis and subsequent lactic acid accumulation (Krishna et al., 1999).  
In addition to malaria induced depletion of gluconeogenic substrates, liver damage associated 
with malaria may further precipitate hypoglycaemia. The rapid proliferation and migration of 
malaria parasites from one hepatocyte to another during the life cycle of the malaria parasite has 
been shown to cause hepatocellular damage (Dekker et al., 1997). The possible leakage of the 
intracellular contents of the damaged hepatocytes to the extracellular fluid may occur, as 
evidenced by studies that have reported elevated plasma concentrations of liver enzymes such as 
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aspartate and alanine transaminases as well as alkaline phosphatase to be indicative of such liver 
damage (Kausar et al., 2010). The liver is key organ involved in the maintenance glucose 
homeostasis; hence any hepatocellular damage may impair glucose homeostasis. The liver plays 
a major role in breaking down the activated insulin-receptor complex. Hepatocellular damage 
may, therefore, result in slow insulin receptor recycling, thereby precipitating hypoglycaemia 
(Onyesom and Agho, 2011). 
1.4.2 Effects of CHQ on glucose homeostasis 
The effects of CHQ on glucose homeostasis remain obscure to date. Current literature evidence 
generated from both human and animal experimental studies have reported conflicting findings 
on the effects of CHQ on blood glucose concentration. Smith et al, 1987, showed that CHQ has 
no effect on plasma glucose concentration in non diabetic subjects (Smith et al., 1987) while a 
separate study using experimental animals and high doses of CHQ,  reported that CHQ causes 
hyperglycaemia (Obi et al., 2003). This conflicting evidence is indicative that CHQ induced 
effects on glucose homeostasis remain unclear.  
 
Davis, 1997, has reported d that CHQ reduced basal plasma glucose levels and increased basal 
plasma insulin levels, possibly mediated through decreased insulin clearance and increased 
peripheral uptake of glucose (Davis, 1997). However, a short term study which lasted for 4 
weeks, gave different results. These investigators reported decreased blood glucose 
concentrations during the first week of study which returned to baseline levels thereafter for the 
duration of the study (Jimmy et al., 2007). Jarzyna et al, 2001, reported increased peripheral 
glucose disposal and reduced insulin resistance in insulin-dependent diabetes mellitus in 
experimental animals (Jarzyna et al., 2001). 
 
Numerous studies, therefore, seem to suggest that CHQ may induce hypoglycaemia through 
varied and unclear mechanisms (Knutson, Ronnett and Lane, 1985; Davis, 1997; Jarzyna, 
Kiersztan, Lisowa and Bryla, 2001). The suggested CHQ induced hypoglycaemia has been 
ascribed to decreased insulin degradation (Knutson, Ronnett and Lane, 1985) or increased insulin 
secretion. (Davis, 1997). Bevan et al, 1995, has reported that hypoglycaemia may be due to CHQ 
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induced extension of the life span of CHQ-insulin activated complex (Bevan et al., 1995). CHQ, 
being a diprotic base, rapidly accumulates in acidic lysosomes and endosomes thereby elevating 
lysosomal pH. An elevation of lysosomal pH compromises the optimal activity of lysosomal 
hydrolases that degrade hepatic insulin, with a concomitant increase in plasma concentration of 
intact insulin (Knuston, Ronnet and Lane, 1985). Smith et al, 1987, has also reported that non 
insulin dependent diabetic patients that were given CHQ, had increased plasma insulin 
concentration with a concomitant improvement in their glucose tolerance (Smith et al., 1987). 
CHQ has also been shown to increase insulin secretion via rapid accumulation in the pancreas, 
thereby having a direct effect on the beta cells of islets of Langerhans (Asamoah et al., 1990). 
  
CHQ induced hypoglycaemia has also been ascribed to inhibition of gluconeogenesis due to 
CHQ induced hepatocellular damage (Jarzyna, Kiersztan, Lisowa and Bryla, 2001). CHQ 
induced hepatocellular damage may lead to inhibition of key gluconeogenic enzymes; glutamate 
dehydrogenase and glucose-6-phosphatase (Jarzyna et al., 2001). It may also lead to decreased 
transport of pyruvate into hepatocyte mitochondria (Jarzyna et al., 2001) with a concomitant 
decrease of gluconeogenesis, which may eventually cause hypoglycaemia. 
 
In summary, administration of oral CHQ in a malaria patient could possibly have a major 
impact on the patient’s glucose homeostasis as evidenced by the fact that both the disease itself 
and the drug may be having independent effects on this system. However, as will be discussed 
in later sections, alternative and novel CHQ delivery methods such as transdermal delivery 
could avert the aforementioned adverse effects of oral CHQ on blood glucose homeostasis. 
This is due to the controlled and sustained release of CHQ from this formulation, thereby 
averting the challenges of dose dumping associated with oral CHQ delivery.  
As such, this study sought to investigate and distinguish between pathophysiological effects of 




1.5 Adverse renal effects        
Falciparum malaria is a complex disease with a broad clinical spectrum, involving several 
pathophysiological changes which include, capillary endothelial damage, increased vascular 
permeability, impaired renal microcirculation, haemodynamic alterations, haematologic changes, 
and immunologic responses(Boonpucknavig and Sitprija, 1979; Weller et al., 1992; English et 
al., 1996; Prakash et al., 1996; Basoum, 2000;  Prakash et al., 2002; Naqvi et al., 2003; Das, 
2008; Ogbadoyi and Tsado, 2009; Idonije et al., 2011).  Renal involvement in malaria varies 
widely due to the complexity of the disease (Boonpucknavig and Sitprija, 1979; Basoum, 2000). 
On the other hand, impairment of renal function has also been independently ascribed to CHQ 
treatment. This is, therefore, indicative of the need to distinguish between the pathophysiological 
effects of malaria and chloroquine on renal function. 
 
1.5.1 Malaria induced adverse renal effects      
The specific effects of acute falciparum malaria on renal impairment remain obscure to date 
(Newton et al., 1991, Newton et al., 1994). There are various complicated pathophysiological 
mechanisms in the pathogenesis of malaria that have been shown to be responsible for the 
reported effects of malaria on renal function (Barsoum, 2000). There are two major renal 
syndromes associated with malaria, namely, a chronic and progressive glomerulopathy and acute 
renal failure (Boonpucknavig and Sitprija, 1979; Barsoum, 2000). Renal disturbances in acute 
renal failure may be attributed to impaired renal microcirculation. (Boonpucknavig and Sitprija, 
1979; Prakash et al., 1996; Barsoum, 2000; Prakash et al., 2002; Ekeanyanwu and Ogu, 2010)   
Malaria cute renal failure has also been attributed to haemoglobinuria caused by massive 
intravascular haemolysis and glomerular lesions as a result of immunologic reaction to parasites 
(Boonpucknavig and Sitprija, 1979; Barsoum, 2000). The non specific effects of fever have also 
been shown to be responsible for previously reported fluid and electrolyte disorders in malaria 
acute renal failure (Barsoum, 2000). 
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Malaria acute renal failure is associated with varying degrees of fluid and electrolyte imbalances 
characterized by extracellular fluid volume depletion, azotaemia and hyponatraemia 
(Boonpucknavig and Sitprija, 1979; Prakash et al., 1996; Das, 2008). 
Suggested mechanisms involved for malaria induced hyponatraemia include increased plasma 
concentration of AVP characterized by hypervolemia, high urine sodium concentration and 
hyperosmotic urine (Prakash et al., 1996; Elsheikha and Sheashaa, 2007, Ehrich and Eke, 2007, 
Das, 2008). Renal ischaemia and tubular obstruction by haemoglobin casts byproducts of RBC 
haemolysis in malaria, have also been shown to be involved in the development of malaria acute 
renal failure. In the early stages of acute malaria renal failure, constriction of the renal vascular 
bed and splachnic blood vessels occurs (Boonpucknavig and Sitprija, 1979; Das, 2008) leading 
to renal ischaemia. The resultant renal ischaemia causes a decrease in urine volume, urinary 
sodium excretion, increased urine osmolality, and decreased GFR mediated via malaria induced 
increases in the sympathetic activity (Elsheikha and Sheashaa, 2007, Ehrich and Eke, 2007, Das, 
2008). Acute malaria renal failure is also associated with blood hyperviscosity resulting from 
decreased deformability of parasitized erythrocytes which leads to decreased blood flow in renal 
microcirculation (Elsheikha and Sheashaa, 2007, Ehrich and Eke, 2007, Das, 2008). 
 
1.5.2 CHQ induced adverse renal effects      
Acute administration of CHQ has been shown to increase urine flow rate and protein excretion 
(Ngaha, 1982). We have previously shown that acute administration of CHQ causes natriuresis, 
without affecting urine output (Musabayane et al., 1993, Musabayane et al., 1996). We have also 
reported CHQ stimulated AVP secretion following acute CHQ administration (Musabayane et 
al., 2000c). CHQ reportedly suppressed AVP induced cyclic adenosine monophosphate (cAMP) 
production at the level of the hormone receptor complex (Musabayane et al., 2000c). Our 
previously reported absence of antidiuresis despite CHQ induced increases in plasma AVP 
concentration may be explained by this mechanism. (Musabayane et al., 1996; Musabayane et 
al., 2000c). CHQ antagonises AVP induced cAMP generation in the inner medullary collecting 
ducts. The result is the inability of AVP to increase  the concentration of intracellular cAMP, 
thereby inhibiting the antidiuretic action of the hormone (Musabayane et al., 2000c).. 
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Additionally, we have shown that  AVP-induced increases in renal Na+ excretion are mediated 
via V1 receptors (Musabayane et al., 2000b). 
 
On the other hand, CHQ induced NO has inhibitory effects on cAMP production with an overall 
effect of making the collecting duct unresponsive to the action of vasopressin. However, Ahmed 
et al, 2003 have attributed CHQ’s diuretic, natriuretic effects and its ability to increase both GFR 
and plasma vasopressin to its ability to stimulate NO secretion. The ability of CHQ to directly 
inhibit cAMP generation while stimulating NO production, accounts for its overall modulation of 
renal tubular response (Ahmed Ashton & Balment, 2003a). Overall, Ahmed et al., 2003, 
attributes the effects of CHQ and vasopressin secretion to be a nitric oxide dependent effect 
(Ahmed Ashton & Balment, 2003a). Chronic administration of CHQ, has been reported to, cause 
Na+ and Cl- retention and reduction in both GFR and blood pressure. Sodium retention is 
expected to increase extracellular fluid volume and subsequently increase MAP (Musabayane et 
al., 1994). Surprisingly, MAP was reportedly reduced due to extensive vasodilatation that occurs 
following CHQ administration, (Ahmed Ashton & Balment, 2003a). 
 
1.6 Adverse cardiovascular effects  
Malaria induced cardiovascular impairment has been generally associated with metabolic 
disturbances attributable to abnormalities in the host’s RBC membranes, the parasite’s 
consumption of nutrients and cofactors, haemodynamic and immunologic disturbances. CHQ has 
also been shown to have adverse cardiovascular effects (Sofola et al., 1981, Mubagwa and Adler, 
1988, Sofola, 2008). Therefore, there is need to distinguish between the pathophysiological 








1.6.1 Malaria induced adverse cardiovascular effects 
P. falciparum infection is generally associated with cytoadherence and sequestration of pRBCs 
and unparasistised RBCs within coronary microcirculation microcirculation (Dondorp et al., 
2000, Dondorp et al., 2004). The blood vessels are small, resulting in microvascular pathology 
and obstruction to coronary blood flow. Infected RBCs tend to stick to uninfected RBCs, 
forming rosettes, which may clog the microcirculation microcirculation (Dondorp et al., 2000, 
Dondorp et al., 2004). The overall result is tissue hypoxia, which may lead to anaerobic 
respiration, lactic acid production and eventually generation of reactive oxygen species (Clark 
and Cowden 2003).Uyemura et al., 2000 have previously suggested that malaria induced lactic 
acid production may result in depressed mitochondrial respiration  (Uyemura et al., 2000). The 
overall result is increased lipid peroxidation and oxidative stress (Arun-Kumar and Das, 1999). 
We speculated that an increase in oxidative stress may alter the lipid profile status and blood 
pressure of malaria infected animals.  
 
1.6.2 CHQ induced adverse cardiovascular effects 
CHQ has been shown to be associated with cardiac nerve impulse conduction disturbances 
(Sanguinetti and Jurkiewicz, 1990, Shah, 2005, Owens and Nolin, 2006). Literature evidence has 
demonstrated that CHQ may delay ventricular depolarization resulting in widening of the QRS 
complex, particularly the QT prolongation (Sanguinetti and Jurkiewicz, 1990, Shah, 2005, 
Owens and Nolin, 2006). The ability of CHQ to cause conduction disturbances has also been 
demonstrated by Mubagwa and Adler, 1988, who reported that CHQ increased heart rate in a 
dose dependant manner. They suggested the effects to be mediated via muscarinic receptors 
(Mubagwa and Adler, 1988).  Sofola, 2008, also reported that CHQ prolonged the PR interval on 
the ECG and caused bradycardia in a dose dependent manner, suggesting that beta-adrenergic 
blockade renders the heart more vulnerable to the actions of CHQ (Sofola et al., 1981, Sofola, 
2008). However, following intravenous administration, only prolongation of QRS interval has 
been reported (Bustos et al., 1994). The ability of CHQ to cause conduction disturbances is 
further shown by studies that have demonstrated that at low micromolar concentrations, CHQ 
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lengthened the action potentials of cat Purkinje fibres, and increased automaticity (Benavides-
Haro and Sanchez-Chapula, 2000, Sanchez-Chapula et al., 2001).  
 
CHQ has also been shown to cause hypotension (Looareesuwan et al., 1986; Marquardt and 
Albertson, 2001; Messant et al., 2004). CHQ induced hypotension was observed during CHQ 
self- poisoning, where there was both tachycardia and bradycardia with atrioventricular block. In 
such cases, intraventricular conduction delay as indicated by widening of the QRS interval has 
also been consistently reported. Such patients present with shock resulting from CHQ’s ability to 
cause peripheral vasodilatation and negative inotropic effect (Riou et al., 1988, Riou et al., 
1989). Hypotension associated with CHQ is a result of arteriolar dilatation and venodilatation. 
Studies by Abiose et al. demonstrated CHQ induced venodilation via the release of NO in human 
forearm veins (Abiose et al, 1997). The results of this study, further demonstrated that CHQ may 
reduce both preload and afterload when oral dosages above the recommended therapeutic doses 
are taken. Other mechanisms that have been suggested to explain the previously reported CHQ 
induced hypotensive effects, were CHQ ability to cause blockade of alpha receptors and 
increased histamine secretion (Abiose et al, 1997). However, to date, information as to other 
cardiovascular effects of CHQ in malaria setting are still unclear. We therefore, speculated that 
CHQ may affect the plasma lipid profile parameters, which is a more sensitive marker of CVD 
impairment.  
 
Generally, lipid metabolism is a complex but highly regulated physiological process 
(Kwiterovich, 2000).  Dyslipidaemia, which usually leads to development of atherosclerosis, 
may include both lipoprotein overproduction and deficiency manifesting in any one or more of 
the following; elevated total cholesterol, low-density lipoprotein cholesterol (LDL-c), and 
triglyceride levels or as decreased high-density lipoprotein cholesterol (HD-c) level (Grundy, 
1995; Lamarche et al., 1999). The pro atherogenic particles, therefore, include LDL-c, very low 
density lipoprotein (VLDL) and triglycerides, while HDL-c has a protective effect through 
multiple mechanisms (Grundy, 1995; Libby, 2001; Toth, 2005; Natarajan et al., 2010).  HDL-c 
transports cholesterol from peripheral tissues to the liver (Navab et al., 1996, Ross, 1999; Jin et 




Initiation of atherosclerosis occurs via development of a fatty streak which is induced by 
oxidation of LDL in the sub endothelial space (Navab et al., 1996; Holvoet and Collen, 1998; 
Libby et al., 2000). LDL progresses from being minimally modified (mmLDL) to being 
extensively modified (oxLDL) (Schwenke and Carew, 1989; Navab et al., 1996). The mmLDL 
and inflammatory cytokines promote the secretion of adhesion molecules that induce adhesion of 
monocytes to the endothelial cells. The activated monocytes then migrate into the sub endothelial 
space where they differentiate into macrophages. The result is the formation of foam cells via 
uptake of oxLDL by scavenger receptors located on the surface of macrophages (Ross, 1999; 
Libby et al., 2000). The oxLDL taken up by macrophages are then esterified, stored in lipid 
droplets and then converted into soluble forms or exported to extracellular HDL through the 
action of cholesterol transporters that include ABC-A1. Atherosclerotic lesion progression is a 
result of interactions between macrophage foam cells, Th1 and Th2 cells establish a chronic 
inflammatory process (Ross, 1999). All the cellular components in the vessel wall are then 
subjected to both pro- and anti atherogenic actions of cytokines secreted by lymphocytes and 
macrophages. There is also migration and proliferation of smooth muscle cells from the media to 
the arterial intima, where they form a fibrous plaque via the secretion of extracellular matrix 
proteins (Ross 1999; Esteve et al., 2005). Plaque rupture and thrombosis results from necrosis of 
foam cells derived from macrophages and smooth muscle cells (Ross, 1999; Gau and Wright, 
2006). This leads to the formation of a necrotic core characterized by accumulation of 
extracellular cholesterol. Weakening of the fibrous plague occurs as a result of macrophage 
secretion of matrix metallo-proteinases and neo-vascularization. This leads to plague rapture 
exposing blood components to tissue factor thereby initiating coagulation, recruitment of 
platelets, and subsequent formation of a thrombus (Ross, 1999; Esteve et al., 2005; Gau and 
Wright, 2006). Atherosclerosis may, therefore, eventually lead to cardiovascular complications, 
such as myocardial infarction and stroke. 
 
The effects of CHQ on the plasma lipid profile parameters have remained unclear. Indeed, 
studies on systemic erythematosus (SLE) and rheumatoid arthritis (RA) patients have given 
obscure findings. None of the studies in literature have investigated the effects of CHQ on the 
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lipid profile parameters, in a malaria model. Beynen, 1986 reported that CHQ and its analogues, 
quinacrine and hydroxychloroquine have the ability to treat hypercholesterolaemia (Beynen, 
1986). In SLE patients, CHQ was shown to lower total cholesterol (Wallace et al., 1990, Hodis et 
al., 1993, Petri et al., 1994, Kavanaugh et al., 1997, Rahman et al., 1999, Tam et al., 2000b, Tam 
et al., 2000a). The suggested mechanism for this reduction was via reduction in hepatic 
cholesterol synthesis and preferential reduction in the synthesis of VLDL. In some of the above 
mentioned studies, CHQ and other antimalarial drugs were also able to reduce plasma VLDL 
(Hodis et al., 1993, Tam et al., 2000a). However, reports by Beynen et al, 1986, have also shown 
that CHQ may have beneficial effects by reducing levels of pro atherogenic lipoproteins such as 
LDL-c (Wallace et al., 1990). Some studies have also shown ability of CHQ to increase HDL in 
patients with rheumatoid arthritis (Munro et al., 1997)  as well as in SLE patients (Borba and 
Bonfa, 2001). HDL has cardioprotective properties against development of atherosclerosis. It 
must be noted, however, that the pathogenesis of SLE or RA are different from malaria, hence 
the effects of CHQ on the plasma lipid profile parameters in malaria patients may vary.  
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1.7 Novel chloroquine delivery methods  
Much interest has arisen leading to a continued search for long-acting CHQ preparations to 
modify the dosing schedule (Musabayane et al., 2003). Novel CHQ formulations that allow the 
bitter taste to be masked or avoided provide attractive alternatives (Musabayane et al., 2003). 
One such alternative drug route, transdermal delivery would avert adverse effects discussed 
above attributable to transiently high plasma CHQ concentrations following oral administration. 
1.7.1 Transdermal delivery 
Transdermal delivery refers to delivery of a drug into the systemic circulation via the skin 
(Foldvari, 2000, Benson, 2005, Morrow et al., 2007, Prausnitz and Langer, 2008). This method 
of delivery is an attractive approach for either local or systemic treatment in medicine (Cevc et 
al., 1996). Current literature evidence has shown that the skin is becoming a new frontier for the 
delivery of a wide variety of drugs, thereby avoiding inconvenient, repetitive dosing schedules 
associated with conventional oral delivery and use of hazardous hypodermic needles (Foldvari, 
2000). The ultimate goal of transdermal drug delivery is to ensure that compounds are delivered, 
preferably at a sustained, controlled specific rate, to the systemic circulation (Morrow et al., 
2007, Songkro, 2009). There are numerous advantages which make transdermal delivery the first 
choice drug delivery route over oral delivery (Prausnitz and Langer, 2008).  However, the 
stratum corneum (SC) layer of the skin provides a barrier function, which is the major 
impediment to effective utilization of this delivery route to deliver various drugs. As such, it is 
imperative to discuss the physiology of the skin, possible routes of drug penetration, advantages 
and limitations of this drug delivery route as well as various techniques and methods that can be 
used to enhance drug permeation through the skin. 
 
 
1.7.2 Physiology of the human skin 
To understand drug delivery through the skin one should first become familiar with the structure 
of the skin barrier (Barry, 2001). An understanding of the structure and barrier properties of the 
SC is indispensable in the quest to optimize transdermal drug delivery. The skin, the largest 
organ of the body is comprises of several layers which include the uppermost layer referred to as 
SC, the epidermis, the dermis, and the lower layers of adipose tissue (Powell and Soon, 2002, 
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Powell, 2006, Venus et al., 2010). Human skin is an effective, selective barrier to chemical 
permeation since the primary role of the SC is to provide a substantial diffusional barrier and 
thereby protect the body from by xenobiotics (Powell and Soon, 2002, Powell, 2006, Venus et 
al., 2010). Biophysical, morphological, and biochemical evidence indicates that the SC forms a 
continuous sheath of protein-enriched corneocytes embedded in an intercellular matrix enriched 
in non-polar lipids and organized as lamellar lipid layers (Bouwstra and Honeywell-Nguyen, 
2002). SC is, therefore made up of 10-15 layers of corneocytes whose thickness at any given 
time depends on its state of hydration (Bouwstra and Honeywell-Nguyen, 2002, Menon, 2002). 
The SC layer comprises keratin-rich corneocytes (brick) and an intercellular matrix (mortar) 
composed of long chain ceramides, free fatty acids, triglycerides, cholesterol, cholesterol 
sulphate and sterol/wax esters. This molecular arrangement gives a multi- layered ‘brick and 
mortar’ like elegant structure (Powell and Soon, 2002, Powell, 2006, Venus et al., 2010). The 
intercellular lipid matrix is generated by keratinocytes giving a lamellar structure (Powell and 
Soon, 2002, Powell, 2006, Venus et al., 2010). These multiple, lipid bilayers tend to form 
regions of semi crystalline gel and liquid crystals domain. Therefore, this uniform, ordered 
nature of these biochemicals, especially lipid bilayers maintain and promote the diffusional 
resistance of the SC barrier. Directly below the stratum corneum is the viable epidermis, which 
consists of three layers, the stratum granulosum, spinosum and basale. The epidermis contains 
keratinocytes at varying stages of differentiation, as well as melanocytes, Langerhans cells which 
are important for antigen presentation and immune response, and Merkel cells which are 
involved in sensory perception (Cevc et al., 1996, Venus et al., 2010). Epidermis is the region 
where the transdermally delivered drug can either be absorbed into circulation, metabolized or if 
it is a prodrug, may be activated. In this way, the drug is cleared rapidly from the skin tissues 
(Goodman and Barry, 1989). Underneath the epidermis is the dermis, which consists of 
fibroblasts, endothelial cells and mast cells. These cells are embedded in connective tissue 
composed of mainly collagenous fibres, and this accounts for approximately 70% of the dry 
weight of the skin (Rivierea and Papich, 2001, Trommer and Neubert, 2006) 
 
The SC, therefore, poses a formidable challenge to the formulation of transdermal drug delivery 
systems (Trommer and Neubert, 2006).  However, the presence of intrinsic and extrinsic 
27 
 
proteins, such as enzymes, may affect the lamellar structure (Venus et al., 2010). One very vital 
component of the SC is water which acts as a plasticizer to prevent cracking and in maintaining 
suppleness by generating a natural moisturizing factor (Menon, 2002, Powell, 2006). This state 
of hydration is vital to enable enhanced drug permeation. Several approaches have been utilized 
to facilitate entry of drugs into the lower skin layers, and subsequently into systemic circulation 
(Barry, 2001). There are various routes that a drug can use to penetrate the skin although the 
transport across the continuous SC is the most important.  
1.7.3 Drug transport through the human skin 
There are three potential pathways with which drugs can penetrate the SC, viz: through the sweat 
ducts, via the hair follicles and sebaceous glands (shunt or appendageal route), or directly across 
the SC (Potts and Francoeur, 1990, Potts and Guy, 1992, Songkro, 2009). The bulk of skin 
penetration enhancement techniques continues to focus on drug transport across the continuous 
SC rather than via the appendages as their contribution to a steady state flux of drugs is 
reportedly very minimal (Barrett, 1969, Foldvari, 2000, Barry, 2001). 
1.7.3.1 Routes of drug penetration through the SC 
Drugs can penetrate the SC using either the micro or macro routes (Barrett, 1969). Micro routes 
include intercellular and transcellular delivery routes, whereby the specific pathways followed by 
the drug may be between adjacent cells or traversing through the cells. Most drug penetration 
enhancers tend to disrupt the ordered SC structure in order to promote both intercellular and 
transcellular transport systems (Songkro, 2009). Macro routes of drug penetration refer to 
transport at a large or bulk scale across the SC. The macro routes include transport via the sweat 
ducts and hair follicles which make up the skin appendages, collectively referred to as the shunt 
transport system. This shunt system is generally important for the transport of ions, large polar 
molecules, polymers and colloidal particles(Barry, 2001, Songkro, 2009). Another vital transport 
pathway is directly across the continuous SC, which forms the major route of transdermal drug 
penetration. In this penetration pathway, each drug has to undergo a series of partitioning into 
and diffusing across multiple hydrophilic (keratinocyte) and hydrophobic (lipid lamellae) 
domains. This is reportedly a major limitation to transdermal delivery of most drugs, as the 
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permeation pathway is dependant not only on the physicochemical properties of the drug, but of 
the vehicle as well (Trommer and Neubert, 2006). Generally drug permeation across the SC 
obeys Fick’s first law, which is dependent on solubility and partition coefficient of a drug (Barry, 
2001, Songkro, 2009). Transdermal delivery is highly feasible for drugs with a low relative 
molecular mass, hence for most drugs, there is need to manipulate the physicochemical 
properties of both the drug and its vehicle. Transdermal delivery has several advantages relative 
to oral delivery route as discussed in the next section.  
1.7.3.2 Advantages of transdermal delivery 
Drug delivery across the skin offers a non invasive, user-friendly alternative to conventional oral 
delivery because the skin presents a relatively large and readily accessible surface area for drug 
absorption (Benson, 2005). Transdermal drug delivery eliminates the variables such as pH, food 
intake and gastro-intestinal motility (Songkro, 2009). Secondly, transdermal delivery route 
circumvents the hepatic metabolism and is, therefore, suitable for drugs with a low 
bioavailability as well as eliminating the need for high initial drug dosages  (Barry, 2001). 
Transport of drugs across the skin can also give a constant, controlled and sustained drug input, 
thereby decreasing the variations in drug plasma levels, thus reducing the side effects particularly 
of drugs with a narrow therapeutic window (Rivierea and Papich, 2001). Patient compliance may 
be increased due to the decreased frequency of dosing. This enhances the possibility of 
significantly improving the treatment of certain diseases as well as greatly increasing the 
patient’s comfort due to possibility of self administration of the drug (Prausnitz and Langer, 
2008). Transdermal delivery also circumvents HIV and other infectious disease transmission, 
which is possible when using hypodermic needles, as well as avoiding disposal challenges 
associated with these hypodermic injections (Prausnitz and Langer, 2008).  
1.7.3.3 Limitations of transdermal delivery 
Some drugs, however, may be inappropriate for transdermal administration such as those 
hindered by their physicochemical properties of being too large, highly polar or charged, having 
insufficient lipid solubility, or a tendency to cause direct skin irritation (Prausnitz and Langer, 
2008). Such drugs may also have unfavourable pharmacokinetic or pharmacodynamic behaviour 
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such as having a very rapid clearance relative to achievable rate of skin delivery, first-pass 
cutaneous biotransformation, a requirement for intermittent high peak and low trough blood 
profiles or simply insufficient potency (Songkro, 2009). Therefore, candidates for passive 
transdermal delivery share three common properties, which include, effectiveness at relatively 
low doses, molecular mass less than 500 Dalton and lipophilicity. Due to the aforementioned 
drug penetration barrier of the intact SC, only potent drugs have been administered through the 
skin to date. Transdermal delivery has undergone three generations of development, which 
promises a greater possibility to deliver drugs of varied physicochemical properties in the near 
future (Prausnitz & Langer 2008). The use of penetration enhancers is a second generation of 
transdermal delivery method (Prausnitz & Langer, 2008). These penetration enhancers will be 
independently discussed in the next section. 
 
1.8 Optimizing transdermal delivery 
Diffusion of drugs across the skin is a passive process; hence compounds with low solubility and 
affinity for the hydrophilic and lipophilic components of the SC would, theoretically partition at 
a slow rate. Such difficulties may be overcome by addition of a chemical adjunct to the delivery 
system that would promote drug partitioning into the SC (Songkro, 2009). One long-standing 
approach for improving transdermal drug delivery uses penetration enhancers, also called 
sorption promoters or accelerants (Prausnitz and Langer, 2008). The role of penetration enhancer 
inclusion in transdermal formulations has been well documented (Songkro, 2009). 
Optimization of drug permeation across the skin may be achieved using techniques that improve 
drug-vehicle interactions. By passing or removal of the SC and use of physical and electrically 
assisted methods are other techniques that may be used. Chemical penetration enhancers may be 
applied to modify the SC, thereby optimizing drug permeation. 
Drug- vehicle based techniques include careful drug selection based on its physicochemical 
properties, use of pro drugs and ion pairs, modification of drug-vehicle interactions and chemical 
potential of the drug, use of eutectic systems, complexes, liposomes, vesicles and particles. On 
the other hand, techniques based on SC modification include, bypassing or removal of SC, 
physical and electrically assisted methods, as well as use of chemical penetration enhancers to 
cause SC lipid fluidization and hydration. However, the major focus of the discussion in the 
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current study will be on chemical penetration enhancers. Emphasis will be on penetration 
enhancers that were used in the current study, which include; a water based occlusive matrix 
patch system, dimethylsulphoxide (DMSO), eucalyptus oil, sodium oleate and vitamin E. 
Therefore, only a brief overview of the various categories of physical penetration enhancement 
techniques will be given in the next section followed by a discussion on the various classes of 
chemical penetration enhancers 
1.8.1 Physical penetration enhancement techniques 
 
The use of physical techniques to enhance drug penetration falls into various categories. The first 
category is based on drug and vehicle interactions (Barry 2001). Successful drug and vehicle 
interactions hinges on careful drug or pro-drug selection based on its physico chemical properties 
(Barry, 2001). Favourable physico chemical properties of a transdermally delivered drug or pro-
drug include low relative molecular mass of less than 600 Dalton, adequate solubility in both 
water and oil and low melting point. The above mentioned properties may enhance the 
thermodynamic activity and partition coefficient of the drug in the SC thereby promoting drug 
permeation. Chemical potential of transdermally delivered drug must also be carefully 
considered as it has a bearing on the steady state drug flux in the SC (Songkro, 2009). 
Thermodynamic activity of a such drugs, may also be enhanced by addition of a co solvent, 
which evaporates at the skin surface, creating a supersaturated solution 
(Moser et al., 2001). Formulations, such as these, require incorporation of a polymer to prevent 
crystallization of the supersaturated solution, so as to increase the metastability of the 
transdermal formulation. Using ion pairs, complex coarcervates as well as eutectic systems as 
physical drug penetration enhancement techniques is also based on the manipulation of drug 
vehicle interactions. Use of ion pairs involves the addition of an oppositely charged species to a 
charged drug, leading to the formation of a neutral ion pair which can permeate and partition 
more readily through the SC. This complex dissociates in the viable epidermis, thereby rapidly 
releasing the parent charged molecule into the dermal and epidermal layers (Megwa et al., 
2000a, Megwa et al., 2000b, Valenta et al., 2000, Sarveiya et al., 2004).  Formation of eutectic 
mixtures is based on the principle that eutectic mixtures have a lower melting point, which serves 




Another category of physical drug penetration enhancement techniques is based on the use of 
vesicles and particles such as liposomes, transferosomes, ethosomes, and niosomes. Liposomes 
are phosphatidylcholine based colloidal particles that are formed as concentric biomolecular 
layers capable of encapsulating drugs (Touitou et al., 1994). Transferosomes, on the other hand 
are produced when a surfactant or an edge activator is incorporated onto a liposome. They are 
smaller than liposomes hence they have been shown to penetrate the SC at a faster rate than 
liposomes (Cevc, 1996, Cevc, 2003). Ethosomes are liposomes with high alcohol content. This 
makes their ability to penetrate deeper tissues and the systemic circulation to be enhanced 
(Dayan and Touitou, 2000, Touitou et al., 2000, Touitou et al., 2001). This is because ethanol 
fluidizes both the ethosomal lipids and those of SC, thereby allowing the drug to penetrate the 
disorganized lipid bilayers (Touitou et al., 2000, Touitou et al., 2001). Niosomes on the other 
hand are vesicles that are composed of nonionic surfactants. Niosomes are currently being 
investigated for the carrier of various drugs and cosmetics (Shahiwala and Misra, 2002). The 
above mentioned nanoparticles have recently been shown to enhance SC penetration due to 
increased skin hydration. The powderject system that fires high velocity solid particles through 
the SC into to lower skin layers using a supersonic shock wave of helium gas is an example of a 
physical drug permeation enhancement technique (Burkoth et al., 1999). 
 
Bypassing or complete removal of the SC is another class of physical penetration enhancement 
techniques. The category is based on the concept of a microneedle array, ablation of SC and 
follicular delivery. A microneedle device is a jet propelled particle at high-velocity with 
compressed gas carrying drug particles into the skin (Cross and Roberts, 2004). This device is 
designed to penetrate the horny layer of the skin without stimulating nerves or breaking the 
horney layer (Langer, 2000, Barry, 2001). Ablation of SC involves removal of the horny layer 
using a laser, adhesive tape or chemical peels (Cevc, 1996). Drug uptake into the skin can, 
therefore, be measured using tape stripping protocol (Touitou et al., 1998). Follicular delivery 
refers to the use of pilosebaceous unit for drug delivery. The pilosebaceous unit comprises of the 
hair follicle, hair shaft and sebaceous gland and also referred to as the shunt drug delivery route. 
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Follicular delivery transports a drug directly to its target site, such as ‘naked’ DNA delivery for 
gene therapy (Hoffman, 2000). 
 
The last category of physical penetration enhancement techniques includes physical and 
electrically assisted drug delivery methods. Ultrasound based techniques such as phonophoresis 
and sonosoresis, iontophoresis, electroporation, magnetophoresis and photochemical wave are 
examples of physical and electrically assisted physical techniques that aid drug permeation 
(Mitragotri, 2000). Ultrasound based techniques use ultrasound energy at low frequencies to 
massage topical formulation onto the SC as their penetration enhancement mechanism (Byl, 
1995, Mitragotri, 2000, Mitragotri and Kost, 2000). Their mechanism of action involves 
cavitation. As the formulation is massaged onto the skin using ultrasound, cavities formed may 
collapse producing shock waves which may disturb the SC lipid packing, thereby increasing the 
volume available to aid drug penetration. They also cause an increase in lipid fluidity of the SC 
(Menon et al., 1994, Songkro, 2009). Iontophoresis on the other hand refers to the driving of 
charged molecules into the SC, via shunt routes due to application of a small direct current to a 
drug containing electrode in direct contact with the skin (Guy, 1998, Barry, 2001). 
Electroporation refers to the application of short micro- to milli-second electrical pulses of 
approximately 100-1000 V/cm to create transient aqueous pores in lipid bilayers (Prausnitz et al., 
1996). The aqueous pores that are formed enable drugs to be transported through the horny layer 
(Prausnitz et al., 1996). Magnetophoresis and photochemical wave use the principle of delivering 
drugs in a pulsatile mode into the SC using magnetic or microchip based systems. This is due to 
that photomechanical waves or laser-generated stress waves cause transient permeabilisation of 
the SC. In this way, diamagnetic drugs or other molecules can be moved into the skin.(Langer, 
2000). The major limitation of physical and electrically assisted physical drug permeation 
techniques is e that the safety margin for home use still needs to be evaluated (Barry, 2001). The 
safety concerns generally associated with physical penetration enhancement techniques has over 





1.9 Chemical penetration enhancers 
Generally, chemical penetration enhancers have been widely investigated and evaluated, making 
them a safer and more practical alternative to the use of physical drug penetration enhancement 
techniques. Various chemical penetration enhancers will be discussed in the next section. 
Attention will, however, be given to the selected penetration enhancers that were incorporated 
into the transdermal formulation that was used in the current study. The selected chemical 
penetration enhancers have varied mechanisms of action as they belong to different classes of 
compounds. It is, therefore, imperative; to first discuss the mechanisms of action generally 
employed by various chemical penetration enhancers.  
1.9.1 Mechanisms of action for chemical penetration enhancement 
The release of a therapeutic agent from a transdermal formulation applied to the skin surface and 
its transport to the systemic circulation is a multistep process which involves dissolution within 
and release from the formulation,  partitioning into the skin’s outermost layer, the SC, diffusion 
through the SC, partitioning from the SC into the aqueous viable epidermis, diffusion through the 
viable epidermis and into the upper dermis, and finally the uptake into the local capillary 
network and eventually the systemic circulation. Mechanisms through which these enhancers 
increase drug penetration through the SC is best summarized in the lipid-protein partitioning 
(LPP) theory (Barry, 1991, Williams and Barry, 1991). The theory has proposed that penetration 
enhancement is via disruption of the intercellular lipid bilayer, interaction with intracellular 
proteins of the SC and the improvement of the partitioning of a drug, coenhancer, or cosolvent 
into SC.  
 
Chemical penetration enhancers may act on the SC lipids because most enhancers have a polar 
head and a long alkyl chain (Trommer and Neubert, 2006). These chemical enhancers increase 
the permeability of the SC by simply fluidizing the lipid structure which results in a disordered 
structure, forming microcavities within the lipid bilayer, thereby increasing the diffusion 
coefficient of the drug or penetrant (Songkro, 2009). Other enhancers have the ability to 
penetrate the lipid bilayer and mix homogenously with the bilayer, while some others at high 
concentration pool within the lipid domains, creating permeable pores. These pores offer less 
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resistance for polar or hydrophilic penetrants (Ongpipattanakul et al., 1991). Another mechanism 
through which enhancers increase the penetrant’s penetration is by causing perturbation of the 
enzyme systems responsible for the formation of the SC lipids (Barry 2001). An understanding 
of the structure activity relationships of chemical enhancers plays a major role in optimal 
penetration enhancement. Such enhancement is dependent on chain length, polarity, alkyl chain 
unsaturation and the presence of particular functional groups in the enhancer molecule (Aungst, 
1989). Lipophilic excipients can, therefore, easily penetrate the lipid bilayer of the SC. The 
lipophilic excipients, however, also encounter opposition to penetrate the aqueous environment 
of the viable epidermis which can be managed by use of organic solvents like propylene glycol. 
The use of cholesterol and fatty acid inhibitors can also increase excipient or permeant 
penetration. The clinical applications of most penetration enhancers, however, is limited by that 
they also cause irritation to the skin (Kanikkannan and Singh, 2002). In summary, the 
penetration enhancers, penetrate the lipid bilayer, rotates, vibrates, translocates thereby forming 
microcavities and increasing volume available for drug diffusion.  
 
Protein modification is another mechanism of action for some chemical enhancers. The 
intracellular matrix of SC consists of corneocytes, which are made up of keratin filaments. A 
chemical enhancer penetrating the intracellular matrix may interact and bind to these keratin 
filaments thereby disrupting the order existing inside the corneocyte (Benson, 2005). This has an 
effect of increasing the diffusion coefficient and permeability of the penetrant. Modification of 
the peptide/protein molecules in the lipid bilayer domain is the other mechanism suggested. 
However, all these enhancers, as already mentioned have a limitation of inducing skin irritancy.  
Finally, chemical enhancers may promote drug partitioning in the SC, as their mechanism of 
action. Promotion of partitioning has an overall effect of enhancing the ability of the penetrant to 
partition into and solubilise within the SC. The chemicals do this by shifting the solubility 
parameter of the skin, moving it closer to that of the penetrant, thereby increasing its solubility 
and flux (Liron and Cohen, 1984a, Liron and Cohen, 1984b). Additional chemical penetration 
enhancer mechanisms may generally include action of the enhancer on desmosomal connections 
between corneocytes as well as altering metabolic activity within the skin to aid drug penetration 
across the SC (Benson, 2005). In summary, there are many potential sites and modes of action 
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that have been identified for skin penetration enhancers such the intercellular lipid matrix in 
which the enhancers may disrupt the packing motif, the intracellular keratin domains or through 
increasing drug partitioning into the tissue, in which case the enhancer, may act as a solvent for 
the drug within the membrane.  
Generally, the ideal or desirable properties of penetration enhancers include that that they should 
be non-toxic, non-irritating and non allergenic (Trommer and Neubert, 2006). They should 
ideally work rapidly, and the activity and duration of effect should be both predictable and 
reproducible. They should have no pharmacological activity within the body such as any ability 
to bind to receptor sites (Prausnitz and Langer, 2008, Songkro, 2009). The penetration enhancers 
must work unidirectionally by allowing therapeutic agents into the body whilst preventing the 
loss of endogenous material from the body (Barry, 1991). When removed from the skin, barrier 
properties should return both rapidly and fully. The penetration enhancers should be appropriate 
for formulation into diverse transdermal preparations, thus should be compatible with many 
different drugs (Rivierea and Papich, 2001). They should be cosmetically acceptable with an 
appropriate skin ‘feel’(Barry, 1991). However, none of the available chemical penetration 
enhancers possess all the properties, hence need for continued study in this area is still of prime 
importance.  
 
There are various classes of chemical penetration enhancers, such as phospholipids, 
pyrrolidones, surfactants, amides, polyols, esters, alcohols, oxazolidines and epidermal enzymes. 
Polymers, lipid synthesis inhibitors, azone and its derivatives as well as biodegradable enhancers 
are additional classes of chemical penetration enhancers. The discussion in the next section, 
however, will be limited to the classes of the chemical penetration enhancers that were used in 
the current study. The classes of chemical penetration enhancers that were incorporated into the 
transdermal formulation used in current study include water, oleic acid which is a fatty acid, 
eucalyptus oil which is an essential oil, vitamin E which is an antioxidant as well as DMSO, 






1.9.1. 1. Water 
Water has been shown to be the safest and widely used penetration enhancer for both hydrophilic 
and lipophilic drugs and pemeants (Barry, 2001). The penetration enhancement mechanism of 
water is via increasing the hydration and permeability of the horny layer(Scheuplein and Blank, 
1973). Water content of the SC varies depending on the humidity of the external environment. 
Water in the SC exists in different states, such as ‘bound’ water which is associated with 
structural elements of this layer. The remaining is ‘free’ water, which is available to act as a 
solvent within the membrane for polar or hydrophilic drugs (Kalia et al., 2000). Additionally, the 
skin contains the natural moisturizing factor (NMF). This is a humectants mixture of the 
hygroscopic amino acids and their derivatives, including salts that are naturally found in the SC. 
The purpose of this NMF is to retain skin water in conjunction with functional groups of keratin 
proteins that bind water molecules. The overall effect is maintenance of skin pliability. Increased 
water content of the skin increases SC hydration which in turn causes swelling and therefore 
opening the SC membrane lipid structure. Clearly, free water molecules therefore, alter the 
solubility of the drug, thereby modifying drug partitioning from its vehicle, into SC. Logically, 
this is expected for hydrophilic drugs, and not lipophilic pemeants  (Barry, 2001, Songkro, 
2009). Water may also use other mechanisms other than just distorting the lipid bilayer to aid 
drug penetration. The possible mechanisms varies from the corneocytes taking up water and 
swelling to creation of a continuous aqueous pore pathway comprising lacunar dormains that are 
embedded in the lipid bilayers. This pathway enhances drug permeation through the SC 
(Songkro, 2009). Caution must, however, always be taken whenever rodents hairless skin are 
used to mimic the human skin for transdermal delivery of various drugs. This is because, upon 
raising hydration of the SC, the rodent skin increases drug flux by higher magnitude than the 
human skin (Bond and Barry, 1986, Bond and Barry, 1988).  
For transdermal drug delivery systems, hydration is increased by occlusion of the skin using 
plastic films; paraffin, oils, water-in-oil or oil-in-water emulsions as well as waxes that are used 
as components of ointments (Songkro, 2009). A water-in-oil system prevents transepidermal 
water loss while an oil-in-water emulsion donates a water molecule to the SC. Various occlusive 
films have been designed and experimentally tested. Of these, are films that used plastic or oily 
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vehicle that were shown to achieve optimal SC hydration thereby giving maximal pemeant 
penetration (Barry, 2001).  
1.9.1.2. Fatty acids  
Oleic acid belongs to this class of penetration enhancers. Long chain fatty acids have reportedly 
been used as penetration enhancers (Larrucea et al., 2001). Extensive studies by Aungst, 
concluded that saturated alkyl chain lengths of C10–C12 attached to a polar head group yield 
potent enhancers, while C18 is the optimum chain length for  unsaturated alkyl chains (Aungst, 
1989, Funke et al., 2002). The cis configuration of unsaturated alkyl chains disturbs the lipid 
packing motif more than the trans conformation. Various drugs have so far been delivered with 
the aid of fatty acids as a penetration enhancer (Funke et al., 2002). Oleic acid has also been 
shown to enhance penetration of various drugs at minute concentrations, in addition to exhibiting 
synergistic effects when used in conjunction with PG (Sintov et al., 1999). Analogues of fatty 
acids also possess penetration enhancement activity (Takahashi et al., 2002). Fatty acids interact 
and modify the lipid domains as their mode of action as well as existing in this layer as pools or a 
separate phase, thereby facilitating permeation of hydrophilic drugs. When used at high 
concentrations, oleic acid tends to phase separate, meaning that they tend to pool within the lipid 
domains forming permeable pores. These pores enhance transport of various molecules (Barry, 
2001). Studies have evaluated the effects of physico chemical properties of many fatty acids, 
such as their chain length, polarity, unsaturation of the alkyl chain as well as presence of special 
functional groups in aiding drug penetration (Kanikkannan et al., 2000). 
 
1.9.1.3. Essential oils, terpenes and terpenoids 
Eucalyptus oil belongs to this class of penetration enhancers. The mechanism of action of this 
class of compounds, involves the disruption of the elegant lipid bilayer structure as well as 
forming separate pools within the bilayer to create hydrophilic channels (El Maghraby, 2008). 
Terpenes, which are found in essential oils, have also been shown to act as penetration enhancers 
in addition to their general use as flavourants and fragrance agents (Williams and Barry, 1991, 
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El-Kattan et al., 2000, Cal et al., 2001, Jain et al., 2002, Monti et al., 2002, Morimoto et al., 
2002).  
1.9.1.4 Anti-oxidants 
Vitamin E belongs to this class of penetration enhancers. Generally, it is believed that Vitamin E 
decreases the gel state order of phospholipid membranes (Thiele and Ekanayake-Mudiyanselage, 
2007). Vitamin E intercalates within the lipid bilayer, to disorder gel phase lipids without 
causing any irritation to the skin (Triverdi 1995). The overall effect is to increase the 
permeability of the skin, aiding drug penetration into SC (Thiele and Ekanayake-Mudiyanselage, 
2007).  In addition to drug penetration enhancement and antioxidant properties, vitamin E also 
possesses emollient properties (Triverdi 1995) 
 
1.9.1.5 Sulphoxides 
DMSO belongs to this class of chemical penetration enhancers. DMSO is generally known to be 
a powerful aprotic solvent with a unique ability to hydrogen bond with itself rather than with 
water (Songkro, 2009). It is a colourless, odourless and hygroscopic compound. As such, in most 
pharmaceutical applications, DMSO is generally used as a ‘‘universal solvent’’, or as a co-
solvent in formulations or alone  (Barry, 2001). DMSO can act as a penetration enhancer for both 
hydrophilic and lipophilic permeants. The use of DMSO, as a penetration enhancer is 
concentration dependant, with concentrations above 60% recommended whenever it is used as a 
co-solvent in drug formulations (Songkro, 2009). DMSO has also been shown to have a rapid 
mode of action (Barry, 2001). The compound has inherently multiple, but complex mechanisms 
of action. DMSO reportedly denatures proteins, changing their structure from a helical 
conformation to an h sheet (Barry, 2001). Based on its physicochemical structure, the DMSO 
molecule interacts with the head groups of the lipid bilayer thereby distorting its packing 
geometry. Such an interaction is possible because DMSO is highly polar (Benson, 2005). 
Furthermore, in the SC membranes, DMSO, may promote drug partitioning from its vehicle into 
this universal solvent. DMSO also penetrates the lipid bilayer, rotates, vibrates, translocates 
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thereby forming microcavities and increasing volume available for drug diffusion (Prausnitz and 
Langer, 2008). 
 
There are numerous compounds such as dimethylacetamide and dimethylformamide whose 
structure is related to DMSO. However, as is the case with DMSO, such analogues may also 
cause irreversible SC damage (Southwell and Barry, 1983). Unlike DMSO, 
decylmethylsulphoxide, does not cause irreversible SC damage although its effects are also 
concentration dependent, just like its parent molecule (Barry, 2001). Various investigators have 
reported that DMSO continues to be used to deliver various drugs to date (Barry et al., 1984). 
The major limitation to the use of DMSO is that at concentrations above 60%, it may cause 
erythema as well as denaturation of SC proteins(Pathan and Setty, 2009). Furthermore, the 
metabolite, dimethylsulphide produces a foul odour on the breath (Songkro, 2009). DMSO 
possibly has greater effects on the rodent skin than the human skin. This is because the hairless, 
rodent plasma membrane is more fragile, yet DMSO is a relatively harsh compound. It is 
common in the pharmaceutical industry to produce transdermal formulations that have more than 
one penetration enhancer, in order to benefit from the synergistic effects of their combinations as 
discussed in the next section. 
 
1.9.1.5 Synergistic effects of penetration enhancers 
Transdermal formulations generally incorporate two or more penetration enhancers from 
different classes of chemical compounds in order to benefit from synergistic effects of such 
combinations (Songkro, 2009). Reports indicate that various combinations of enhancers have 
multiplicative or synergistic effects (Harrison et al., 1996, Barry, 2001). In some formulations, 
synergistic effects of combining physical and chemical penetration enhancers has also been 
employed (Barry 2001). Various enhancement strategies have varied effects on the transdermal 
drug delivery (TDD) formulation or the skin in general. It is vital to note at this stage, that 
caution must always be exercised in the choice of a penetration enhancer for any drug delivery 
system. This, is due to the fact that they may cause skin irritancy and in some rare cases, toxicity 
(Sloan et al., 1986). This has limited the clinical application of most enhancers; hence safer 




In summary, synergistic effects of various penetration enhancers may alter the release of a drug 
from a formulation, depending on the chemical potential of the drug as well as causing SC lipid 
fluidization. Some enhancers act as biochemical modulators in the viable epidermis, while 
vasoactive drugs modulate blood flow rate, thereby influencing rate of drug absorption into 
systemic circulation. The transdermal formulation used in this study employed the synergistic 
effects of combining chemicals in different classes of penetration enhancers, thereby benefiting 
from their varied modes of action to aid the penetration of CHQ across the SC (Songkro, 2009).  
1.9.1.6 Transdermal drug delivery systems 
Transdermal delivery systems (TDDs) are drug containing technical devices that form a temporal 
unit with the skin (Barry 2001). The majority of TDDs act through increasing SC hydration to 
open up the pores of the horny layer, thereby aiding drug penetration (Roy et al., 1996, 
Venkatraman and Gale, 1998, Wokovich et al., 2006, Padula et al., 2007, Mishra et al., 2009). 
There are various TDDs that increase the hydration status of the SC, namely, lipophilic 
materials, emulsifying bases, water oil emulsions, oil-water emulsions, absorption bases, 
moisturizing factors, humectants and powders, occlusive dressings, and occlusive patches (Barry 
2001). Lipophilic based TDDs consist of paraffin, oils, fats, waxes, fatty acids, alcohols, esters 
and silicones. Combining these constituents in lipophilic based TDDs prevents water loss from 
the SC, thereby producing full hydration. The overall effect is therefore an increase in skin 
permeability. The other TDDs attain full SC hydration through various mechanisms ranging 
from donating water molecules to preventing water loss as seen in occlusive patches (Songkro, 
2009). TDDs based on the concept of occlusion include occlusive dressings and occlusive 
patches. These TDDs have been shown to effectively prevent water loss from the SC, thereby 
having an effect of causing full hydration of the skin. An occlusive dressing is made up of a 
plastic film, and an imperforated waterproof plaster where as the occlusive patch is an example 
of transdermal patches(Prausnitz and Langer, 2008). The current study used an occlusion based 




1.9.1.6.1 Occlusive transdermal drug delivery patch systems 
Generally, a TDDs consists of several components, including the active ingredient, backing 
membrane, pressure-sensitive adhesive and the permeation enhancer (Barry, 2001). Examples of 
occlusive TDDs include the reservoir systems and the matrix systems (Rhee et al., 2008). 
Transdermal patches come in different forms and designs such as single layer drug in adhesive 
form, multilayer drug in adhesive form, vapour patches, reservoir patches and transdermal 
patches. Reservoir patch systems consist of drug deposits surrounded by insoluble polymer 
membranes, which are the control release elements (Roy et al., 1996, Venkatraman and Gale, 
1998, Wokovich et al., 2006, Padula et al., 2007, Mishra et al., 2009). The mechanism 
controlling release of the drug molecule is diffusion. Examples of polymers used in this system 
are ethylcellulose, hydropropyl cellulose, waxes, silicone derivatives and ethyl vinyl acetate .On 
the other hand, matrix patch systems are those in which the drug is intimately mixed with an 
inert polymer. Drug release in these systems also occurs by diffusion, but is controlled by the 
properties of the polymer. These are also referred to as monolithic systems (Rhee et al., 2008). 
Matrix systems can either be hydrophobic or hydrophilic. The occlusive matrix system has 
several advantages which include that the entire system can be made to be thin and elegant.  The 
matrix system can also be made very comfortable to wear. Additionally, matrix systems exhibit 
flexibility in the choice of backing layers (Venkatraman and Gale, 1998). Matrix TDDs can be 
made up of synthetic or natural polymers such as pectin, which was the polymer of choice for 
this study. The chemistry of pectin, as well as how its physicochemical properties are modified 
by other components of the matrix patch will be discussed in the next section. Such 
modifications include varying degrees of pectin methylation, amidation and addition of Ca2+ 
ions. 
 
1.10 Transdermal delivery polymers 
1.10.1 Chemistry of pectin 
Pectin (polygalacturonic acid) is an anionic polysaccharide present in the cell wall of most plants 
(Ridley et al., 2001). It is non-toxic, almost totally degraded by colonic bacteria and is not 
digested by gastric or intestinal enzymes (Cummings et al., 1979). Pectin structure is 
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heterogeneous with respect to its chemical structure and molecular weight (Ridley et al., 2001). 
The poly (d-galacturonic acid) moieties in pectin are bonded via a 1-4-glycosidic linkage (Ridley 
et al., 2001, Matia-Merino et al., 2004, Lofgren et al., 2006). Pectin also contains neutral sugars 
such as L-rhamnose, which are either inserted in or attached to the main chains. The carboxyl 
groups in pectin molecules are partially in the methyl ester form. Some of the carboxyl groups 
may be converted to carboxamide groups, when ammonia is used in the process of de-
esterification, producing amidated pectin (Ridley et al., 2001). The properties of pectin are 
dependent on the degree of amidation (DA) and degree of methylation (DM), which denotes the 
amide and methyl groups attached to carboxyl and hydroxyl groups of the pectin molecule 
respectively. Pectin forms water-insoluble complexes with several drugs and may be a useful 
additive for sustained-drug release preparations (Ridley et al., 2001). Colonic bacteria are able to 
degrade pectin, hence there has been renewed interest to investigate use of pectin as a carrier for 
drugs whose target delivery site is the colon (Rubinstein et al., 1993, Munjeri et al., 1998, 
Musabayane et al., 2000b). The possible use of pectin in transdermal delivery formulations has 
also been suggested (Musabayane et al., 2003). The gelling properties of pectin are influenced by 
various factors, which include the DA, DM, pH of the solution, temperature as well as the 
presence of cations such as calcium ions (Ridley et al., 2001). The various ways that can be used 
to optimize the gelling properties of pectin are discussed in the next section. 
1.10.2 Optimisation of gelling properties of pectin 
Gelling of pectin can be induced by acid or by cross-linking with calcium ions (Sriamornsak, 
1998). Ionisation of carboxylate groups of pectin is repressed in an acidic environment or when 
the pH of the solution is low. Unionized pectin carboxylate groups do not repel each other over 
their entire chains, and thus can associate over a portion of their chains to form acid pectin gels 
(Matia-Merino et al., 2004). Acidic solutions reduce the hydration of pectin, meaning there are 
fewer water molecules that are incorporated into the pectin interchain entanglements. The 
subsequent increases in the pH of the solution causes ionization of the polycarboxylate groups, 
enabling them to react with cations such as calcium ions to form calcium pectinate (Sriamornsak, 
1998). The interaction of calcium ions and the carboxylate groups in pectin involves 
intermolecular chelate binding of the cation leading to the formation of macromolecular 
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aggregates (Rubinstein et al., 1993). In the colon, calcium pectinate can readily be degraded by 
bacterial pectinases which are activated by the presence of calcium ions in the pectin molecule. 
Generally, the amount of calcium ions added into the pectin gels also has an impact on the 
strength of the gels and the release of incorporated drugs  
44 
 
1.11 Basis of the present study 
 
We speculated that use of pectin CHQ matrix patches may eliminate the development of 
transiently high initial systemic drug concentrations associated with oral CHQ administration. 
Such a sustained, controlled, slow release of the CHQ from the matrix patch may circumvent 
development of the adverse effects of CHQ on glucose homeostasis, renal and cardiovascular 
function that are associated with oral delivery. We also envisaged that the sustained, slowly 
released CHQ concentration from pectin CHQ matrix patch eliminates P. falciparum parasites.  
There are currently no reports in literature that have shown the effects of transdermal application 
of pectin CHQ matrix patches on glucose homeostasis, renal and cardiovascular function in a 
malaria rat model. Therefore, the present study, was designed to compare the effects of oral and 
transdermal delivery of CHQ on glucose homeostasis, renal and cardiovascular function in a 
malaria rat model were investigated. 
 
1.12. Aims of the study 
 
The main objective of the current study was to compare the effects of transdermal CHQ patch 
and oral chloroquine in the management of malaria as assessed by the ability to clear parasites of 
P. berghei infected rats. The other aims were to investigate and distinguish between the patho 
physiological effects of malaria and CHQ treatments on blood glucose and plasma insulin 




MATERIALS AND METHODS 
2.1. Materials 
2.1.1 Drugs and chemicals  
Drugs and chemicals were sourced as indicated:  
 
Grindsted pectin LA 410 (Danisco, Palackého, Czech Republic); chloroquine diphosphate 
(C18H26CIN3·2H3PO4), sigmacote, dimethyl sulphoxide (C2H6SO), anthrone and glycogen 
powder, type II, from oyster, giemsa stain (Sigma-Aldrich Chemical Company, Missouri , St 
Louis, USA); calcium chloride (CaCl2), potassium hydroxide (KOH), sodium sulphate (Na2SO4), 
sodium hydroxide (NaOH), dimethyl sulphoxide (DMSO), d-glucose, potassium dihydrogen 
phosphate (KH2PO4) and 95% ethanol (C2H5OH) (Merck Chemicals (PTY) LTD, Johannesburg, 
South Africa); vitamin E (Pharma Natura (PTY) LTD, Johannesburg, South Africa); eucalyptus 
oil (Barrs Pharmaceutical Industries cc, Cape Town, South Africa); diethyl ether (C4H10O) (NT 
Laboratory Supplies (PTY) LTD, Johannesburg, South Africa); sulphuric acid (H2SO4) (BDH 
Chemicals LTD, Poole, England), halothane (Fluorothane®, AstraZeneca Pharmaceuticals 
(PTY) LTD, Johannesburg, South Africa), and The Ultrasensitive Rat Insulin ELISA kit -(DRG 
Instruments, GmbH, Marburg, Germany). All chemical reagents were of analytical grade. 
 
2.2. Ethical consideration 
Ethical clearance was obtained from the University of KwaZulu-Natal’s Ethics committee 
(reference 018/09 Animal; 017/10 Animal and 10/11/Animal see Appendices I, II and III). 
 
2.3. Animals 
Male Sprague-Dawley rats (90-150 g) bred and housed in the Biomedical Resource Unit of the 
University of KwaZulu-Natal, Westville campus were used in the study. The animals were 
maintained under standard laboratory conditions of constant temperature (22±2 °C), CO2 content 
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of <5000 p.p.m., relative humidity of 55±5%, and illumination (12 h light/dark cycles) and the 
noise levels of <65 decibels. The animals had free access to standard rat chow (Meadows, 




2.4.1 Preparation of the pectin-CHQ matrix patch 
 
The pectin-CHQ matrix patch was prepared with slight modifications according to the method 
previously described by (Musabayane et al., 2003). Briefly, pectin (4g) was dissolved in 100ml 
de-ionised water with agitation at 700 rpm using a mixer (Scientific Engineering cc, 
Johannesburg, 51A Richard rd, South Africa). Various doses of chloroquine disphosphate, 5g, 
10g and 20g were then added with further mixing and agitation in separate beakers that were 
placed in a water bath at 37OC for 30 minutes. Subsequently, dimethyl sulphoxide (3ml, vitamin 
E (1.5ml) and eucalyptus oil (1.5ml) were added. Following 4 hours of further mixing and 
agitation, an aliquot of (10ml) was transferred to a petri dish and frozen at -5oC for 18 hours. 
After freezing, a 2% CaCl2 was added on top of the frozen pectin and left to stand at room 
temperature for 10 min to allow for cross linking. The patches were then stored in a refrigerator 
at 2oC until use. Before the commencement of the experiments, the dorsal region of the rat was 
shaved for the application of the pectin CHQ matrix patch.  The effects of transdermal CHQ 
were assessed by placing patches on the shaved area and securing them in place with adhesive 
hydrofilm (Dischem, Cnr of Le Roux & Stay rd Glen Austin, South Africa) and rat jackets 
(Braintree, Scientific, inc , Massachusetts, USA). The control group was sham applied with CHQ 
free pectin matrix patch.  
 
2.4.2. Determination of % CHQ incorporation  
Pectin CHQ matrix patch of known volume and surface area was dissolved in 100ml of Sorensen 
buffer (pH 7.4), with shaking for 30 minutes at 700rpm in order to speed up the dissolution 
process. 2 ml of the mixture was withdrawn to measure chloroquine spectrophotometrically 
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(Shimadzu Corporation, Kyoto, Japan) at 343nm. The blank contained CHQ free pectin hydrogel 
patches dissolved in Sorensen buffer (pH 7.4) (Musabayane et al., 2003).  
 
2.5. Induction of malaria 
Malaria was induced in male Sprague-Dawley rats (90-150g) by a single intra-peritoneal 
injection of P berghei (105 parasitised RBC). (Gumede et al., 2003). The rodent CHQ 
susceptible P. berghei parasite was supplied by Professor Peter Smith (University of Cape 
Town, Division of Clinical Pharmacology, South Africa). Control animals were injected with 
the phosphate buffered saline vehicle. Successful malaria induction was confirmed by 
microscopic examination of Giemsa stained thin smears of the rat tail blood.  Percentage 
parasitaemia of greater than or equal to 20% was considered as a stable malaria state before 
commencing any experimental procedures. 
 
2.6. Experimental design 
Acute effects of CHQ on blood glucose (0-4h) and short-term effects on renal and cardiovascular 
functions (3 weeks) were monitored in separate groups of non-infected and P. berghei infected 
male Sprague-Dawley rats (n= 6 in each group). 
 
2.7. Acute studies 
2.7.1 Oral glucose tolerance test (OGTT)( protocol 
OGT responses were carried out as previously described (Musabayane et al., 2007) with slight 
modifications. The animals were divided into non infected and P. berghei infected groups. The 
non infected and P. berghei infected groups were further divided into, control group, oral CHQ 
and patch treated groups. The treatment protocol for all groups was as follows;  the animals were 
fasted for 18 h, followed by measurement of blood glucose (time 0) and subsequent loading of 
glucose (0.86 g/kg, p.o.). OGT responses were monitored in separate groups of animals treated 
with various doses of oral CHQ (30, 60 and 120 mg/ kg or pectin-CHQ matrix patch (29, 53 and 
72 mg/kg). CHQ diphosphate solution was prepared by dissolving CHQ diphosphate powder in 
deionised water and given to the rats by means of a soft tube passed orally into the stomach 
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(Musabayane et al., 1994). Oral CHQ control animals were given de-ionised water, while CHQ 
matrix patch control animals were sham applied with CHQ free pectin matrix patch. Blood 
glucose concentrations were measured over a 4-hour period; every 15 minutes for the first one 
hour and subsequently every hour. Blood was obtained via tail prick for blood glucose 
concentration measurements (Acsensia Elite Blood Glucose Testing Strips, Bayer®) and Bayer’s 
Glucometer Elite® (Elite (Pty) Ltd, Health Care Division, Isando, South Africa). 
 
2.7.2. Effects of CHQ on plasma insulin  
Plasma CHQ and insulin concentrations were determined in blood samples of separate groups of 
non- infected animals treated with oral CHQ (60mg.kg b.wt) and pectin matrix patch (53mg/kg). 
The orally treated group was given CHQ diphosphate solution twice daily, 8 hours apart for 5 
consecutive days. Treatment with pectin CHQ matrix patch was a once off application of the 
patch on the first day of the 5 day treatment period at 09h00. The patch was placed on the shaved 
area of the rat back neck and was left on for 5 day treatment period. The animals (n=6 ) were 
sacrificed at the end of 0.25; 0.5; 1; 3 and 5days via halothane inhalation (Fluorothane®, Astra 
Zeneca pharmaceuticals (Pty) LTD). Blood was collected by cardiac puncture into pre-cooled 
heparinized tubes for blood glucose concentration and plasma insulin determination. The 
collected blood was centrifuged (Eppendorf centrifuge 5403, Schwerte, Germany) at 4 °C, 3000g 
for 15 minutes and separated plasma was stored at -70 °C in a Bio Ultra freezer (Snijers 
Scientific, Tilburg, Netherlands) until insulin assay. Effects of CHQ on plasma insulin on  
P. berghei infected animals was not done in the current study.  
 
2.8 Short term studies 
Male Sprague-Dawley rats (90g-120g) were used in the non-infected and P berghei infected, 
control and treated groups. The animals were housed individually in Makrolon polycarbonate 
metabolic cages (Techniplasts, Labotec, South Africa) for three weeks at the Biomedical 
Resource Unit, University of KwaZulu- Natal, (n=6 in each group) with free access to water and 
standard rat chow ad libitum (Meadows, Pietermaritzburg, South Africa). The rats were 
maintained on a 12 h dark/light cycle. 
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The effects of oral CHQ treatment (60mg/kg) and pectin CHQ matrix patch (53 mg/kg) were 
investigated in both the non infected and P berghei infected animals. The 21 day studies were 
divided into pre-treatment (days 0-7), treatment (days 8-12) and post treatment (days 13-21) 
periods. The separate groups of animals were treated with oral CHQ and pectin CHQ matrix 
patches as described in section 2.7.2. 
 
2.8.1 Short-term effects of CHQ treatments on: 
2.8.1 1. Parasitaemia 
Daily malaria parasite density was measured in separate groups of P berghei infected animals 
throughout the 21 day experimental period. Thin blood films stained by Giemsa method as 
previously described by Gumede et al., (2003) were examined. Briefly, a small incision in the tip 
of the rat tail was made followed by placing a small drop of blood on a microscope slide. This 
was smoothly and uniformly smeared using a second microscope slide. The blood film on the 
slide was subsequently dried in a stream of warm air, fixed in methanol for 30 s and then stained 
in Giemsa stain for 10–45 min. Finally the blood film was dried in air and observed using an 
Olympus microscope (Olympus cooperation, Tokyo, Japan) with a x50–x100 oil immersion 
objective. Extreme caution was taken to distinguish parasites from inclusions in RBC such as 
Howell-Jolly bodies, platelets on top of RBC, or from precipitated stain. An eyepiece graticule 
was used to obtain accurate counts. Counting of 5 microscope fields was followed by calculation 
of the percentage of infected RBCs.  
 
2.8.1 .2 Physico metabolic changes 
The animal weights, and the amounts of food and water consumed were measured at 09h00 
every 3rd day during the pre treatment and post treatment periods, and daily during the treatment 
period. Blood glucose concentration was measured 6 hours after treatment in all groups of 
animals using blood glucose testing strips (Acsensia Elite Blood Glucose Testing Strips, 
Bayer®) and Bayer’s Glucometer Elite® (Elite (Pty) Ltd, Health Care Division, Isando, South 
Africa). The 24 h urine volume and urinary urea, creatinine and electrolytes (Na+, K+) outputs 
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were also measured. Haematocrit was measured using heparinised capillary tubes. Briefly, blood 
was collected via a tail prick. The sealed capillary tubes were then centrifuged for 3 minutes at 
3000g with a Micro-haematocrit centrifuge (346 MSE Centrifuge Manufacturer, London, UK). 
Haematocrit was then determined by calculating the percentage of the total blood volume to 
packed cell volume. The measurements were done at 09h00 every 3rd day during the pre 
treatment and post treatment periods, and daily during the treatment period. 
2.8.1.3 Mean Arterial Pressure (MAP) 
MAP was monitored every 3rd day at 09h00 in separate groups of conscious Sprague Dawley rats 
for three weeks using the non invasive tail cuff method (IITC Model 31 Computerized Blood 
Pressure Monitor, Life Sciences, Woodland Hills, California, USA) as previously described 
(Musabayane et al., 2007). During the treatment period, MAP was measured daily at 09h00. The 
unit comprises the IITC hardware system that utilizes an automatic scanner pump, photoelectric 
tail cuff sensors and an amplifier. The blood pressure of the tail vein of the animal is measured 
and the output is recorded in form of a chart that is displayed on the connected computer 
monitor. To ensure accuracy and consistency, the equipment was calibrated each day before 
commencing MAP measurements. The animals were warmed in an enclosed chamber (IITC 
Model 303sc Animal Test Chamber IITC, Life Sciences, Woodland Hills, California) for 30 
minutes at ±30°C before taking three blood pressure recordings of each animal as previously 
described by Gondwe et al., (2008). 
 
2.8.2 Terminal studies 
Separate groups of non fasted conscious animals (n=6) were sacrificed on days 0, 7, 8, 9, 10, 12, 
14 and 21, at 24 hours after the last treatment for oral CHQ administration and after a once off 
patch application on the first day of treatment. The sacrifice procedure was performed by 
halothane inhalation in an anaesthetic chamber with 100 mg/kg of halothane (Fluorothane®, 
Astra Zeneca 2002) pharmaceuticals (Pty) LTD) for 3 minutes. Blood was collected by cardiac 
puncture into pre cooled heparinised tubes and centrifuged for 15 minutes at 3500g and 4 °C to 
separate the plasma (Eppendorf centrifuge 5403, Germany). The plasma samples were stored in a 
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Bio Ultra freezer (Snijers Scientific, Tilburg, Netherlands) at -70 °C until assayed. 
Concentrations of plasma electrolytes (Na+, K+, Cl-), urea, creatinine, CHQ and insulin were 
measured. Plasma concentrations of the lipid profile parameters were also measured.  
The harvested liver, gastrocnemius muscle tissue (1-1.5g), kidney, heart and spleen were 
weighed gravimetrically (Mettler balance PC 180-insruments, Protea Laboratory Services, South 
Africa) and snap frozen in liquid nitrogen. The liver and gastrocnemius muscle tissue (1-1.5g) 
used for glycogen determination were immediately placed on ice (Ngubane et al., 2011). 
 
2.9. Laboratory analyses 
 
2.9.1. Biochemical measurements 
2.9.1.1 Determination of plasma CHQ concentration 
Following the treatment of separate groups of animals with oral CHQ and pectin CHQ matrix 
patch, measurement of plasma CHQ concentration was conducted. Sigmacote was used to coat 
all glassware to prevent adsorption of CHQ to the glass surfaces. Plasma CHQ determination 
was carried out by means of a double extraction process as previously described by Musabayane 
et al., 2000 (Musabayane et al., 2000) with slight modifications. Briefly, 0.2ml of plasma sample 
was added to a 250ml separator flask followed by 1ml of 25% KOH and 10mls of diethyl ether. 
The solution was then mixed and allowed to stand for 2 minutes to allow the immiscible layers to 
separate followed by acidification of the solution using. 2ml of 1% H2SO4. Absorbance of 
resultant aqueous solution was then read using a spectrophotometer (Ultraviolet Novaspec II 
spectrophotometer (Biochrom LTD, Cambridge, England) against a plasma blank at 343nm.  
 
2.9.1.2 Electrolytes measurements 
Determination of urine and plasma Na+, K+, CI, urea and creatinine concentrations were 
measured using the Beckman Coulter (Synchron LX20 Clinical Systems, Fullerton, Carlifornia, 
USA). The principle of creatinine estimation is based on reaction of creatinine and sodium 
picrate to form creatinine picrate while that of urea estimation is based on the hydrolytic 
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degradation of urea in the presence of urease. For all the urea and electrolytes measurements, 
standard kits and reagents were supplied by Beckman Coulter, Dublin, Ireland. Glomerular 
filtration rate (GFR) was assessed by creatinine clearance (Ccr). This parameter was calculated 
using a standard formula based on the measurements of the plasma and urinary concentrations of 
creatinine and urine flow rate on different days on which separate groups of animals were 
sacrificed. The samples were prepared by diluting and mixing using a vortex machine (VELP 
Scientifica, Usmate (MB), Italy). To measure both urine and plasma creatinine no dilution was 
necessary.  
 
2.9.1.3 Insulin assay 
Standard enzymatic methods were used to determine  plasma insulin concentration. The assays 
were performed on an ultra sensitive rat insulin ELISA kit (DRG diagnostics EIA-2943 GmbH, 
Marburg, Germany), using reagents supplied by the manufacturer 
 
Principle of the insulin assay 
The kit components included a 96 well plate coated with mouse monoclonal anti-insulin, 
standards, enzyme conjugate, enzyme conjugate buffer, wash buffer, substrate 3,3',5,5'-
tetramethylbenzidine (TMB) and a stop solution. This kit is a solid phase two-site enzyme 
immunoassay which is based on the direct sandwich technique in which two monoclonal 
antibodies are directed against separate antigenic determinants on the insulin molecule.  During 
incubation, insulin in the sample reacted with peroxidase-conjugated anti-insulin antibodies and 
anti-insulin anti-bodies bound to a microtitration well. Unbound enzyme labeled antibody was 
removed by a sample washing step.  Detection of the bound conjugate was done by a reaction 
with 3,3’-5,5’ tetramethylbenzidine.  The reaction was stopped by adding sulphuric acid (0.5M) 
to give a colorimetric endpoint that is read in a spectrophotometer at 450nm. Each determination 
was performed in duplicate for all standards and samples. The lower and upper limits of 
detection were 139 pmol/1 and 960 pmol/1, respectively. The intra-assay analytical coefficient of 
variation ranged from 4.4 to 5.5% and the inter-assay coefficient variation from 4.7 to 8.9%. 
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2.9.1.3 Glycogen determination 
Hepatic and muscle glycogen concentrations were determined as previously described by 
(Ngubane et al., 2011) . Briefly, the tissue samples of 1-1.5g were homogenized in 2ml of 30% 
KOH (30g/100ml) and boiled at 100oC for 30min. Subsequently, ± 0.15ml of 10% Na2SO4 
(10g/100ml) was added to the tissue homogenates, which were then vortexed. 2µl of each sample 
was added to 2µl of 95% of ethanol, 1ml of de-ionised water and 4ml anthrone reagent (0.5g in 
250ml of concentrated H2SO4) to extract the glycogen from the  liver and muscle sample. Blanks 
were prepared in a similar process as tissue samples except that the sample was replaced with 
2µl of de-ionised water. Glycogen powder from oyster, type II was used to prepare standards 
(10-2000 mg/1) which were also treated in the same way as tissue samples described above. All 
solutions were then vortexed and boiled for 10min before measuring absorbance at 540nm using 
a UV mini-1240 spectrophotometer (Shimadzu Corporation, Kyoto, Japan). A glycogen standard 
curve that was prepared as previously described by (Ngubane et al., 2011), was used for the 
extrapolation of all tissue glycogen concentrations. 
2.9.1.4 Lipid profile analysis 
Standard enzymatic methods were used to determine the plasma lipid profile parameters. The 
assays were performed on the Labmax Plano Chemistry analyzer, (Labtest Av. Paulo Ferreira da 
Costa, 600, Brasilia, Brazil) using reagents supplied by the manufacturer 
Plasma enzymatic determination of total cholesterol and triglycerides were followed by 
measurement of HDL-cholesterol using an HDL-c precipitating reagent set (Warnick and Wood, 
1995). LDL-cholesterol and VLDL-cholesterol concentration were then calculated using the 
Friedewald formula:  
• LDL-c = [Total cholesterol (HDL-Triglyceride)/2 mmol] (Friedewald, Levy and Fredrickon, 
1972).  
 




The Friedewald equations are fairly accurate for samples in which the triglyceride concentration 
is less than 4.13mmol/L (Friedewald, Levy and Fredrickon, 1972).  
Principle of total cholesterol assay 
Cholesterol reagent is used to measure cholesterol concentration by a timed endpoint method. 
In the reaction, cholesterol esterase hydrolyses cholesterol esters to free cholesterol and fatty 
acids. Free cholesterol is oxidised to cholestene-3-one and hydrogen peroxide by cholesterol 
oxidase. Peroxidase catalyses the reaction of hydrogen peroxide with 4-aminoantipyrine and 
phenol to produce coloured quinoneimine product. 
Principle of triglycerides assay 
The triglyceride GPO Reagent® is used to measure the triglyceride concentration by a timed 
endpoint method. Triglycerides in the sample are hydrolysed into glycerol and free fatty acids 
by the action of lipase. A sequence of three coupled enzymatic steps using glycerol kinase, 
glycerophosphate oxidase, horseradish peroxidase causes the oxidative coupling of 3, 5 
dichloro-2-hydroxybenzenesulfonic acid with 4-aminoantipyrine to form a red quinoneimine 
dye.  
Principle of HDL-c assay 
The HDL-cholesterol reagent is used to measure the cholesterol concentration by a timed 
endpoint method. In the reaction, the cholesterol esterase hydrolyses the cholesterol esters to 
free cholesterol and fatty acids. The free cholesterol is oxidised to cholesten-3-one and 
hydrogen peroxide by cholesterol oxidase. Peroxidase catalyses the reaction of hydrogen 
peroxide with 4-aminoantipyrine and phenol to produce a coloured quinoneimine product. 
2.9.5 Data presentation 
All data were expressed as means ± standard error of means (SEM). Data for untreated non-
infected and P. berghei infected rats were used as baseline (control values). OGT responses to 
various doses of oral CHQ and pectin CHQ matrix patch as well as effects of oral and 
transdermal CHQ delivery methods on insulin secretion were presented separately for the non-
infected and P berghei infected rats. For chronic studies, the calculation of mean daily fluid 
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voided and urinary amounts of electrolytes excreted and evaluation of GFR assessed renal 
function. The MAP and plasma lipid profile parameters were presented graphically for the 
separate groups of animals to assess the effect of the CHQ delivery routes on cardiovascular 
function. GraphPad InStat Software (version 5.00, GraphPad Software, San Diego, California, 
USA) was used for all statistical analyses. One way one-way analysis of variance (ANOVA) 
followed by Turkey-Kramer multiple comparison test was used to establish statistical 





CHQ effects on blood glucose and malaria parasites  
3.1 General 
This chapter describes the following:  
1) CHQ concentrations in the matrix patch and plasma 
2) acute effects of oral CHQ treatments on OGT responses  
3) short term effects oral CHQ treatments treatment on: 
i. blood glucose and plasma insulin concentrations 
ii. hepatic and muscle glycogen concentrations  
iii. on malaria parasites 
3.2 CHQ concentration in the matrix patch 
The hydrogel matrix patch used in this study had an area of 64mm2 containing CHQ 
concentration of 15.9mg/ml translating into a dosage of 53mg/kg for a 300g rat. The percentage 
CHQ incorporation into the matrix patch was 74%. 
 
3.2 1 CHQ plasma pharmacokinetics. 
Figure 1 A shows plasma CHQ concentration profiles at different time intervals following oral 
CHQ (60mg/kg) treatment, twice daily, 8 hours apart. The peak plasma CHQ concentration was 
achieved after 4 hours. Figure 1B shows the profile of CHQ concentration at different time 
intervals following a single topical application of pectin matrix patch (53mg/kg). Peak plasma 
CHQ concentration was also achieved after 4 hours by comparison to oral CHQ treatment. The 
peak plasma CHQ concentration was sustained for 3 days after treatment with the pectin matrix 




In the post treatment period, plasma CHQ concentrations were significantly reduced in the oral 





Figure 1: Effects of oral CHQ (60mg/kg) treatment (A), and single CHQ matrix patch 
(53mg/kg) (B) on plasma CHQ pharmacokinetics of non infected animals. Values are presented 
as means ± S.E.M. Vertical bars represent S.E.M. (n=6 in each group)  p<0.05 by comparison 






Figure 2:  Plasma CHQ concentrations in animals treated twice daily with oral CHQ (60mg/kg) 
and those treated with a single topically applied CHQ patch (53mg/kg). Values are presented as 
means ± SEM where columns represent means and vertical bars represent SEM (n=6 in each 




3.3 Effects of CHQ treatments on malaria parasites 
 
The effects of oral CHQ and pectin CHQ matrix patch treatment on parasitaemia was 
investigated in P. bergei infected animals. (Figure 3). Figure 3 shows that the peak percentage 
parasitaemia of control animals was reached at day 14 (51.5 ± 16.5%). The control animals were 
sacrificed on day 14 of the experimental period based on preliminary results. As such, all the 
subsequent results showing the infected control animals will be having no post treatment period 
(days 13-21). Following pectin CHQ matrix patch and oral CHQ treatment, the malaria parasites 






Figure 3: Percentage parasitaemia in animals treated twice daily with oral CHQ (60mg/kg) and 
those treated with a single topically applied CHQ patch (53mg/kg) Values are presented as 





3.4 Acute studies 
3.4.1 OGT responses 
Oral glucose tolerance (OGT) responses to various doses of  oral CHQ (30, 60, 120 mg/kg,) and 
topical application of various doses of pectin CHQ hydrogel matrix patch (29, 53, 72mg/kg) 
were monitored in non infected and P. berghei infected male Sprague- Dawley rats.  
 
3.4.2. Effects of CHQ   
Following a glucose load (0.86g/kg) in both the non infected and infected control groups, there 
was an increase in blood glucose concentration, from preloading values. The blood glucose 
concentrations of control animals steadily decreased throughout the 4 hour experimental period 
to concentrations, which were not significantly different from the preloading values at the end of 
the experimental period. All doses of CHQ administered orally (30, 60, 120mg/kg) significantly 
(p<0.05) decreased blood glucose concentrations in both non infected and infected animals in a 
non dose dependent manner (Figures 4 and 5). The highest dose of CHQ (120mg/kg), exhibited 
the most potent effect, decreasing blood glucose concentrations to hypoglycaemic values by the 






Figure 4: Comparison of OGT responses of non infected animals to various doses of oral CHQ 
treatment (30, 60, 120mg/kg) with respective control rats. Values are presented as means where 







Figure 5: Comparison of OGT responses of infected animals to various doses of oral CHQ 
treatment (30, 60, 120mg/kg) with respective control rats. Values are presented as means where 
vertical bars represent SEM (n=6 in each group)  p<0.05 by comparison with control animals 
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3.4.3. Effects of pectin CHQ matrix patch  
All the pectin CHQ matrix patch doses (29, 53, 72mg/kg) significantly (p< 0.05) decreased blood 
glucose concentrations in a non dose dependent manner by comparison to control (Figures 6 and 





Figure 6: Comparison of OGT responses of non infected animals to various doses of transdermal 
pectin CHQ matrix patch treatment (29, 53, 72mg/kg) with respective control rats. Values are 
presented as means where vertical bars represent SEM (n=6 in each group) p<0.05 by 






Figure 7: Comparison of OGT responses of infected animals to various doses of transdermal 
pectin CHQ matrix patch treatment (29, 53, 72mg/kg) with respective control rats. Values are 
presented as means where vertical bars represent SEM (n=6 in each group) p<0.05 by 
comparison with control animals 
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3.5 Short term studies 
3.5.1 General 
Short term studies were carried out in non infected and P. berghei infected male Sprague-
Dawley rats over a 21 day experimental period divided into pre-treatment, treatment and post 
treatment periods. Blood glucose concentrations were measured every 3rd day during the pre-
treatment and post treatment period, and daily during the treatment period. Separate groups of 
non fasted conscious animals (n=6) were sacrificed on days 0, 7, 8, 9, 10, 12, 14 and 21 to collect 
blood for the measurement of plasma insulin concentration and harvesting of the liver and 
gastrocnemius muscle tissues. The harvested tissues were used to measure hepatic and 
gastrocnemius muscle glycogen concentration.. 
3.5.2 Effects of CHQ treatments on blood glucose concentration 
The effects of CHQ treatments on blood glucose concentration were investigated in separate 
groups of non infected and P. berghei infected animals treated with oral CHQ (60 mg/kg) and 
pectin matrix patch (53 mg/kg) in a 21 day experimental study 
The blood glucose concentrations of infected control animals significantly decreased during the 
treatment period by comparison with non infected control animals (Figure 8). 
Oral CHQ treatment, however, significantly decreased the blood glucose concentrations of both 
the non infected and infected animals in comparison to non infected and infected control animals 
(Figure 8A). 
The mean blood glucose concentration of the animals treated with pectin CHQ matrix patch 
remained stable throughout the experiment by comparison to both non infected and infected 
baseline values. Treatment with pectin CHQ matrix patch did not alter the blood glucose 
concentration of both the non infected and infected animals by comparison to oral CHQ treated 
groups. (Figure 8B). In summary, P. berghei infection and oral CHQ treatment reduced blood 
glucose concentrations in male Sprague Dawley rats, while topical application of pectin CHQ 





Figure 8: The effects of oral CHQ (60mg/kg) treatment (A) and single topical application of 
CHQ matrix patch (53mg/kg) (B) on blood glucose concentration. Values are presented as mean 
± S.E.M, where columns represent means and vertical bars represent SEM (n=6 in each group). 
p<0.05 by comparison to baseline control animals. # p<0.05 by comparison with oral CHQ 
treated animals.  
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3.5.2 Effects of CHQ treatments on plasma insulin concentration 
Effects of twice daily oral CHQ (60mg/kg) and a once off application of pectin CHQ matrix 
patch (53mg/kg b.wt) treatment on blood glucose and plasma insulin concentrations in non 
infected animals were investigated in a 21 day study. Separate groups of non fasted conscious 
animals (n=6) were sacrificed on days 0, 7, 8, 9, 10, 12, 14 and 21 to collect blood for the 
measurement of plasma insulin concentration. Plasma insulin concentration of P. berghei 
infected animals was not measured in the current study. 
Oral CHQ administration increased plasma insulin concentration whilst topical CHQ patch did 




Figure 9: The effects of oral CHQ (60mg/kg) treatment and single topical application of CHQ 
matrix patch (53mg/kg) on blood glucose (A) and plasma insulin (B) concentrations. Values are 
presented as mean ± S.E.M, where columns represent means and vertical bars represent SEM 
(n=6 in each group).  p<0.05 by comparison with topically applied CHQ patch treated animals. 
# p<0.05 by comparison with oral post-treatment animals. 
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3.6 Hepatic and gastrocnemius muscle glycogen concentrations 
 
Effects of twice daily oral CHQ (60mg/kg) and a once off application of pectin CHQ matrix 
patch (53mg/kg) treatment on hepatic and gastrocnemius muscle glycogen concentrations in non 
infected and P. berghei infected animals were investigated in a 21 day study. Separate groups of 
non fasted conscious animals (n=6) were sacrificed on days 0, 7, 8, 9, 10, 12, 14 and 21 to 
harvest the liver and gastrocnemius muscle tissues for the measurement of hepatic and 
gastrocnemius muscle glycogen concentrations. 
 
3.6.1 Hepatic glycogen concentration 
3.6.1.1 Effects of CHQ treatments on hepatic glycogen concentration 
Mean hepatic glycogen concentration of both non infected and P. berghei infected control 
animals remained unchanged throughout the study period (Figure 10A). Oral CHQ treatment 
significantly increased hepatic glycogen concentration of non infected group by comparison to 
control animals (Figure 10A). The mean hepatic glycogen concentration of the animals treated 
with pectin CHQ matrix patch remained stable throughout the experimental period by 
comparison to the non infected control and oral CHQ groups (Figure 10B). 
3.6.2 Gastrocnemius muscle glycogen concentration 
3.6.2.1 Effects of CHQ treatments on gastrocnemius muscle glycogen concentration 
Mean gastrocnemius muscle glycogen concentration of both the non infected and P. berghei 
infected control animals did not significantly differ throughout the experimental period. Oral 
CHQ treatment significantly decreased gastrocnemius muscle glycogen concentration of the non 
infected group, during the post treatment period in comparison to baseline and treatment periods. 
Topical application of pectin CHQ patch decreased the gastrocnemius muscle glycogen 
concentration of the infected group, during the post treatment period in comparison to baseline 







Figure 10: The effects of oral CHQ (60mg/kg) treatment (A) and single topical application of 
CHQ matrix patch (53mg/kg) (B) on hepatic glycogen concentration. Values are presented as 
mean ± S.E.M, where columns represent means and vertical bars represent SEM (n=6 in each 






Figure 11: The effects of oral CHQ (60mg/kg) treatment (A) and single topical application of 
CHQ matrix patch (53mg/kg) (B) on gastrocnemius muscle glycogen concentration. Values are 
presented as mean ± S.E.M, where columns represent means and vertical bars represent SEM 
(n=6 in each group). p<0.05 by comparison with baseline control animals.  
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3.7 Hepatic and gastrocnemius muscle mass 
The hepatic and gastrocnemius muscle mass of non infected control animals did not differ 
significantly throughout the experimental period. There was a significant increase in hepatic 
mass of infected control animals and the infected group of animals that were treated with oral 
CHQ or pectin CHQ matrix patch. The hepatic mass of non infected animals treated with oral 
CHQ and pectin matrix patch did not differ significantly throughout the experimental period. 
There were no significant differences in the muscle mass of both non infected and infected 
control animals, as well as the treated groups as shown in Table 1. 
 
Table 1: Hepatic and gastrocnemius muscle masses in separate groups of non infected and 
infected groups of animals treated twice daily with oral CHQ and pectin CHQ matrix patch, for 
baseline/pre-treatment (day 0-7), treatment (day 8-12) and post-treatment (day 13-21) periods. 





Not available (N/A) as the infected control animals were sacrificed on day 14 based on the 
preliminary study findings. 
Organ 
(g/100g tissue) 
Protocol Pre-treatment Treatment Post-treatment 
Non infected 3.93 ± 0.08 3.81 ± 0.08 3.94 ± 0.06 Control 
P. berghei 
infected 
6.74 ± 0.30 8.65 ± 0.43 N/A 
Non infected 3.93 ± 0.08 4.24 ± 0.12 4.46 ± 0.88 Oral 
P. berghei 
infected 
6.44 ± 0.16 7.07 ± 0.17 4.39 ± 0.14 






6.44 ± 0.16 6.38 ± 0.48 5.41 ± 0.30 
 
Non infected 1.13 ± 0.11 1.72 ± 0.11 1.82 ± 0.14 Control 
P. berghei 
infected 
0.94 ± 0.04 1.00 ± 0.09 N/A 
Non infected 1.13 ± 0.11 1.38 ± 0.07 2.08 ± 0.05 Oral 
P. berghei 
infected 
0.99 ± 0.88 1.15 ± 0.04 1.37 ± 0.06 










CHQ effects on renal fluid and electrolyte handling 
 
4.1 General 
This chapter describes the effects of CHQ treatments on: 
i. body weight, food and water intake 
ii. renal fluid and electrolyte handling 
 
4.2 Effects of CHQ on body weight, food and water intake 
The food intake of the non infected control animals did not differ significantly throughout the pre 
treatment, treatment and post treatment periods. However, oral CHQ administration to the non 
infected and infected groups of animals reduced food intake by comparison with animals on 
which the CHQ patch was applied onto the shaved skin area on the back of the neck skin (Table 
2).  
Water intake of the non infected, infected control animals and those rats topically applied the 
pectin matrix patch did not differ significantly throughout the experimental period whilst water 
intake decreased in infected animals that were treated with oral CHQ (Table 2). 
The percentage body weight change of the non infected control animals did not differ 
significantly throughout the experimental period. There was, however, a significant decrease in 
the percentage body weight change of infected animals during the treatment period by 
comparison to the non infected control animals. The percentage body weight changes of both the 
non infected and infected group of animals treated twice daily with oral CHQ, decreased 
significantly by comparison to the non infected control animals and with the pectin CHQ matrix 





Table 2: Effects of twice daily with oral CHQ (60mg/kg) treatment and a single topically 
applied pectin CHQ matrix patch (53mg/kg) on food intake, water intake and body weight 
changes in non infected and P. berghei infected animals (n=6 in each group). Values are 
presented as means ± SEM, where columns represent means and vertical bars represent SEM 
(n=6 in each group) p<0.05 by comparison with control animals. # p<0.05 by comparison with 




N/A as the infected control animals were sacrificed on day 14 based on the preliminary study 
findings. 
Parameter Protocol Pre-treatment Treatment Post-treatment 
 
Non infected 18 ± 0.3  19 ± 1  17 ± 1 Control 
P. berghei 
infected 
14 ± 0.2  10 ± 1.0  N/A 




Non infected 18 ± 0.3  18 ± 0.2  21 ± 1 







Non infected 25 ± 1  22 ± 1  18 ± 1 Control 
P. berghei 
infected 
21 ± 1  18 ± 1  N/A 












Non infected 32 ± 3  31 ± 1  31 ± 1 Control 
P. berghei 
infected 
40 ± 5  -18 ± 1  N/A 




Non infected 28 ± 4  44 ± 1  24 ± 1 







4.3 Effects of CHQ on renal fluid and electrolyte handling 
The results are presented according to the experimental protocol, which was divided into pre 
treatment (baseline, 0-7days), treatment (8-12 days) and post treatment period (13-21 days).  
The 24 hour urine output of non infected animals was stable throughout the 21 day experimental 
period.  P. berghei infected animals had significantly lower 24 hour urine outputs by comparison 
to non infected control animals (Figure 12). Oral CHQ and pectin CHQ matrix patch treatment 
significantly decreased the urine output of both the non infected and P. berghei infected animals 
by comparison to non infected control rats. 
The 24 hour urinary Na+ outputs of non infected and infected control animals remained stable 
throughout the 21 day experimental period. Treatment of non infected animals and infected 
animals with oral CHQ significantly increased the 24 hour urinary Na+ outputs by comparison to 
baseline and non infected control animals (Figure 13). There were no significant differences in 
the urinary Na+ outputs of animals treated with pectin CHQ matrix patch throughout the 
experimental period.  
The non infected control animals had stable 24 hour urinary K+ outputs throughout the 
experimental period. There was a significant increase in the urinary K+ outputs of the infected 
animals during the treatment period by comparison to the non infected control animals. 
Treatment of both non infected and P. berghei infected animals with oral CHQ significantly 
increased the urinary K+ outputs by comparison to the non infected control animals. There were 
no significant differences in the urinary K+ outputs of animals treated with pectin CHQ matrix 
patch throughout the experimental period (Figure 14).  
The urinary creatinine outputs of non infected control animals were stable throughout the 21 day 
experimental period. The infected control animals had significantly increased urinary creatinine 
outputs during the treatment period by comparison to non infected control animals. Treatment of 
non infected animals and infected animals with oral CHQ significantly increased the 24 hour 
urinary creatinine outputs by comparison (Figure 15).  Urinary creatinine outputs of non infected 
animals treated with pectin CHQ matrix patch did not differ significantly throughout the 
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experimental period. The infected animals treated with pectin matrix patch had significantly 
higher urinary creatinine outputs by comparison to non infected control animals. 
Urinary urea outputs of both the non infected and infected control animals did not differ 
significantly throughout the experimental period. Treatment of both infected and non infected 
separate groups of animals with oral CHQ or pectin CHQ matrix patch had no significant effects 
on urinary urea outputs (Figure 16). 
 
In summary the results of the current study have demonstrated malaria infection and oral CHQ 
induced natriuresis with a decrease in urine output. The study has also demonstrated malaria oral 
CHQ induced hyperkalaemia and kaliuresis in malaria infected animals. Malaria infection and 
oral CHQ treatment elevated urinary creatinine outputs. Topical application of pectin CHQ 
matrix patch circumvented natriuresis, hyperkalaemia, kaliuresis and elevation of urinary 





Figure 12: Comparison of the effects of twice daily treatment with oral CHQ (60mg/kg) (A) and 
with a single topically applied pectin CHQ matrix patch (53mg/kg) (B)  on 24 hour urine output 
in non infected and P. berghei infected animals (n=6 in each group). Values are presented as 
means ± SEM, where columns represent means and vertical bars represent SEM (n=6 in each 





Figure 13: Comparison of the effects of twice daily treatment with oral CHQ (60mg/kg ) (A) and 
with a single topically applied pectin CHQ matrix patch (53mg/kg) (B) on 24h urinary Na+ 
outputs in non infected and P. berghei infected animals (n=6 in each group). Values are 
presented as means ± SEM, where columns represent means and vertical bars represent SEM 
(n=6 in each group) p<0.05 by comparison with baseline control animals. ∞p<0.05 by 





Figure 14: Comparison of the effects of twice daily treatment with oral CHQ (60mg/kg) (A) and 
with a single topically applied pectin CHQ matrix patch (53mg/kg) (B) on 24h urinary K+ 
outputs in non infected and P. berghei infected animals (n=6 in each group). Values are 
presented as means ± SEM, where columns represent means and vertical bars represent SEM 
(n=6 in each group) p<0.05 by comparison with baseline control animals. ∞p<0.05 by 






Figure 15: Comparison of the effects of twice daily treatment with oral CHQ (60mg/kg) (A)  
and with a single topically applied pectin CHQ matrix patch (53mg/kg) (B) on 24h urinary 
creatinine outputs in non infected and P. berghei infected animals (n=6 in each group). Values 
are presented as means ± SEM, where columns represent means and vertical bars represent SEM 
(n=6 in each group) p<0.05 by comparison with baseline control animals. ∞p<0.05 by 





Figure 16: Comparison of the effects of twice daily treatment with oral CHQ (60mg/kg ) (A)  
and with a single topically applied pectin CHQ matrix patch (53mg/kg) (B) on 24h urinary urea  
outputs in non infected and P. berghei infected animals (n=6 in each group). Values are 
presented as means ± SEM, where columns represent means and vertical bars represent SEM 
(n=6 in each group)  
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4.4 Effects of CHQ on plasma biochemical parameters 
Table 3 shows the effects of treatment twice daily with oral CHQ (60mg/kg) or with a single 
topically applied pectin CHQ matrix patch (53mg/kg) on plasma biochemical parameters in non 
infected and P. berghei infected animals 
All the plasma biochemical parameters of infected control animals did not differ significantly 
throughout the experimental study. The plasma K+ concentrations  of the P. berghei infected 
group of animals treated twice daily with oral CHQ significantly increased during the treatment 
and post treatment periods in comparison to both the non infected and berghei infected control 
animals and  when compared with  pectin CHQ  matrix patch treated animals (Table 3) 
 
Table 3: Comparison of the effects of treatment twice daily with oral CHQ (60mg/kg ) or with a 
single topically applied pectin CHQ matrix patch (53mg/kg) on plasma biochemical parameters 
in non infected and P. berghei infected animals (n=6 in each group). Values are presented as 
means ± SEM, where columns represent means and vertical bars represent SEM (n=6 in each 
group) p<0.05 by comparison with baseline control animals. # p<0.05 by comparison with 












Control Oral CHQ Patch Protocol Parameter 










Na+ (mmol/l) 137 ± 2  130 ± 4  145 ± 2  134 ± 6  135 ± 2  135 ± 3 
K+ (mmol/l) 5.89 ± 1.00  5.09 ± 0.33  4.26 ± 0.72  5.09 ± 0.33?  5.56 ± 0.31  5.49 ± 0.44 
Urea (mmol/l) 4.5 ± 0.4  32.3 ± 4.0  30.7 ± 1.0  30.6 ± 0.9  30.7 ± 1.0  31.0 ± 1.3 
Creatinine 
(µmol/l) 
26 ± 2  29 ± 1  22 ± 1  28 ± 1  31 ± 1  30 ± 2 





0.82 ± 0.02  1.01 ± 0.03  0.92 ± 0.03  0.83 ± 0.02  0.82 ± 0.02  0.83 ± 0.02 
 
Na+ (mmol/l) 130 ± 5  139 ± 2  136 ± 3  139 ± 3 
 
143 ± 1  142 ± 1 
K+ (mmol/l) 6.51 ± 0.31  4.57 ± 0.88  4.73 ± 0.36  9.96 ±1.86#   5.38 ± 0.41  5.38 ± 0.41 
Urea (mmol/l) 2.9 ± 0.8  29.0 ± 0.5  27.6 ± 0.8  27.6 ± 0.8  27.6 ± 0.8  23.6 ± 1.2 
Creatinine 
(µmol/l) 
23 ± 3  30 ± 4  23 ± 3  27 ± 0.4  24 ± 1  27 ± 4 




0.88 ± 0.04  1.21 ± 0.29  0.88 ± 0.02  0.96 ± 0.02  0.90 ± 0.01  1.05 ± 0.03 
 
Na+ (mmol/l) 133 ± 4  N/A 135 ± 3  138 ± 2  145 ± 1  144 
K+ (mmol/l) 5.41 ± 0.16  N/A 3.73 ± 0.25  13.09 ± 3.06#  5.37 ± 0.79 5.37 ± 0.79 
Urea (mmol/l) 4.2 ± 0.7  N/A 25.6 ± 1.3  25.6 ± 1.2  25.6 ± 1.2  24.0 ± 1.3 
Creatinine 
(µmol/l) 
23 ± 3  N/A 22 ± 1  25 ± 1  24 ± 1  21 ± 1 





0.89 ± 0.02  N/A 0.91 ± 0.02  0.87 ± 0.03  0.84 ± 0.02  1.03 ± 0.05 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Effects of CHQ on cardiovascular function and lipid profile 
 
This chapter describes the effects of CHQ treatments on: 
i. haematocrit 
ii. mean arterial pressure 
iii. lipid profile  parameters 
 
5.1  Haematocrit 
The haematocrit of non infected animals was stable throughout the 21 day experimental period. 
P. berghei infection, however, significantly reduced haematocrit by comparison to non infected 
control animals. Treatment of both non infected and infected animals with oral CHQ 
significantly decreased haematocrit by comparison to non infected control animals (Figure 
17).Topical application of pectin CHQ patch did not significantly alter the haematocrit of the non 
infected animals. The haematocrit of the P. berghei infected group of animals treated with pectin 




Figure 17: Comparison of the effects of twice daily treatment with oral CHQ (60mg/kg) (A) and 
with a single topically applied pectin CHQ matrix patch (53mg/kg) (B) on haematocrit in non 
infected and P. berghei infected animals (n=6 in each group). Values are presented as means ± 
SEM, where columns represent means and vertical bars represent SEM (n=6 in each group) 
p<0.05 by comparison with baseline control animals. ∞p<0.05 by comparison with non 




5.2.1 Oral CHQ treatment  
The MAP of non infected control animals remained stable throughout the 21 day experimental 
period (Figure 18). However, MAP of infected animals significantly decreased during the pre 
treatment and treatment periods by comparison to the non infected control animals. Treatment of 
separate groups of non infected and infected animals with oral CHQ significantly reduced MAP 
by comparison to non infected controls as shown in Figure 18.  
MAP was not measured in the animals treated with pectin CHQ matrix patch treated animals in 




Figure 18: Comparison of the effects of twice daily treatment with oral CHQ (60mg/kg) on 
MAP in non infected animals (n=6 in each group). Values are presented as means ± SEM, where 
columns represent means and vertical bars represent SEM (n=6 in each group) p<0.05 by 




5.3 Lipid profile 
The effects of P. berghei infection and oral CHQ treatment on lipid profile parameters in non 
infected and infected rats were monitored over a 21 day experimental period divided into pre-
treatment, treatment and post treatment periods. Separate groups of non fasted conscious animals 
(n=6) were sacrificed on days 0, 7, 8, 9, 10, 12, 14 and 21 to collect blood for the measurement 
of plasma lipid profile parameters.  
Plasma lipid profile parameters were not measured in the animals treated with pectin CHQ 
matrix patch treated animals in the current study. 
 
5.3.1 Total cholesterol 
The plasma total cholesterol concentrations of the non infected controls remained stable 
throughout the experimental period. Infection of animals with P. berghei significantly increased 
plasma total cholesterol concentrations by comparison to non infected control animals. 
Treatment of non infected animals with oral CHQ did not significantly alter plasma total 
cholesterol concentrations by comparison to non infected animals. However, treatment of 
infected animals with oral CHQ significantly increased plasma total cholesterol concentrations 
by comparison to control animals (Figure 19) 
 
5.3.2 LDL-cholesterol 
The plasma LDL-c concentrations of the non infected controls remained stable throughout the 
experimental period. There were no significant differences in the plasma LDL-c concentration of 
non infected animals treated with CHQ. Infected animals treated with oral CHQ had significantly 







The plasma HDL-c concentrations of non infected control animals did not differ significantly 
throughout the experimental period. Infection of animals with P. berghei significantly reduced 
plasma HDL-c concentration in comparison to non infected control animals. Treatment of 
infected animals with oral CHQ significantly reduced the plasma HDL-c concentration in 
comparison to the non infected control animals (Figure 21). 
 
In summary malaria infection elevated plasma Total cholesterol and LDL-c which were 
exacerbated by oral CHQ treatment. Malaria infection and oral CHQ also reduced haematocrit, 






Figure 19: Comparison of the effects of twice daily treatment with oral CHQ (60mg/kg) on 
plasma Total cholesterol concentration in non infected animals (n=6 in each group). Values are 
presented as means ± SEM, where columns represent means and vertical bars represent SEM 
(n=6 in each group) p<0.05 by comparison with baseline control animals. ∞p<0.05 by 






Figure 20: Comparison of the effects of twice daily treatment with oral CHQ (60mg/kg) on 
plasma LDL-c concentration in non infected animals (n=6 in each group). Values are presented 
as means ± SEM, where columns represent means and vertical bars represent SEM (n=6 in each 
group) p<0.05 by comparison with baseline control animals. ∞p<0.05 by comparison with non 







Figure 21: Comparison of the effects of twice daily treatment with oral CHQ (60mg/kg) on 
plasma HDL-c concentration in non infected animals (n=6 in each group). Values are presented 
as means ± SEM, where columns represent means and vertical bars represent SEM (n=6 in each 
group) p<0.05 by comparison with baseline control animals. ∞p<0.05 by comparison with non 





5.4 Heart masses 
The heart masses of the both the non infected and infected control groups as well as the treated 
groups did not differ significantly throughout the experimental period as shown in Table 4 
Table 4: Comparison of the effects of twice daily treatment with oral CHQ (60mg/kg) and with a 
single topically applied pectin CHQ matrix patch (53mg/kg)  on heart masses in non infected and 
P berghei infected animals (n=6 in each group). Values are presented as means ± SEM (n=6 in 
each group)  
 
 




Protocol Pre-treatment Treatment Post-treatment 
Non 
infected 
0.47 ± 0.02 0.43 ± 0.02 0.46 ± 0.09 Control 
P berghei 
infected 
0.51 ± 0.03 0.53 ± 0.09 N/A 
Non 
infected 
0.47 ± 0.02 0.45 ± 0.43 0.43 ± 0.02 Oral 
P berghei 
infected 
0.43 ± 0.03 0.53 ± 0.01 0.38 ± 0.01 
Non 
infected 













6.0      Discussion 
6.1 General 
The experiments described in this thesis were designed to compare the effects of transdermal 
CHQ patch and oral chloroquine in the management of malaria as assessed by the ability to clear 
parasites of P. berghei infected rats. The other aim of the current study was to investigate and 
distinguish between the patho physiological effects of malaria and CHQ treatments on blood 
glucose and plasma insulin concentration, renal and cardiovascular function in male Sprague-
Dawley rats. P berghei that was used in this study is a rodent malaria parasite that is used for 
experimental purposes to study human malaria as it is regarded as safe because it does not infect 
humans (Janse and Waters, 1995). Weanling male Sprague-Dawley rats (90-120g) were used in 
the current study. This is the age of rats that is highly susceptible to infection by rodent 
plasmodia, developing high parasitaemias that make it possible to assess the curative effects of 
test drugs (Dow et al., 1998; 1999; 2000). A study done by Takeuchi et al, 2011 demonstrated 
that the rat skin may be used as a substitute for the human skin in in vitro skin pemeation studies 
(Takeuchi et al, 2011). Animals were shaved I day prior to experimental procedures on the rat 
back using a shaving machine to avoid pruritis. They were placed in individual cages to avoid 
chances of scratching each other .The experimental  animals had free access to water and 
standard rat chow ad libitum (Meadows, Pietermaritzburg, South Africa). The rats were 
maintained on a 12 h dark/light cycle. The biochemical measurements were done using 
equipment and reagents of international benchmark, as specified by the manufacturers.  
The current study has demonstrated that CHQ can be delivered into systemic circulation 
following a once off topical application of pectin CHQ matrix patch. The results of the current 
study show for the first time that controlled, sustained release of therapeutic doses of CHQ were 
achieved, clearing all the malaria parasites after 3 days of pectin CHQ matrix patch treatment. 
The significance of a once off application of the CHQ patch was the ability to circumvent the 
101 
 
toxic effects of oral CHQ delivery in blood glucose homeostasis, renal function and 
cardiovascular function markers.  
Thus, observations of the current study are of considerable clinical importance as they present 
for the first time, evidence of a novel and feasible alternative method of CHQ delivery. Topical 
application of the patch may ensure completion of courses of therapy as it not only masks the 
bitter taste of CHQ, but provides a convenient dosing schedule. Completion of courses of therapy 
may reduce continued development of P. falciparum resistance to CHQ.  
 
6.2 Plasma CHQ pharmacokinetics 
The doses used were extrapolated from clinical doses that are currently used for the prophylaxis 
and treatment of malaria (WHO, 2006).The peak plasma CHQ concentrations were achieved 
after 6 hours following CHQ administration both orally and topically. Previous studies have 
reported CHQ’s rapid absorption following oral delivery within 4-6 hours (Walker et al., 1983, 
Gustafsson et al., 1983, Augustijns and Verbeke, 1993, Vries et al., 1994). Plasma CHQ 
concentrations decreased within 12 hours following oral CHQ delivery. This finding is in 
agreement with previous observations that reported the ability of CHQ to bind avidly to almost 
all the different epithelial cells and body tissues, attributed to the drug’s large volume of 
distribution in the body (Gustafsson et al., 1983). Ursing et al, (2009) have  also reported the 
ability of CHQ to accumulate in various body tissues such as the liver, lungs, spleen and kidneys 
(Ursing et al., 2009). The detection of CHQ in plasma after 21 days of the experimental period is 
in agreement with previous observations that CHQ has a long half life (McChesney et al., 1967, 
Adelusi and Salako, 1982). 
 
The significance of achieving peak plasma CHQ after 6 hours following a once off topical 
application of pectin CHQ matrix patch is the ability to demonstrate rapid delivery of CHQ to 
systemic circulation from the matrix patch. The mean peak plasma CHQ concentrations 
following pectin CHQ matrix patch administration were sustained for a period of 3 days, 
suggestive of sustained, controlled release of the drug from the pectin CHQ matrix patch (Figure 
1). We have previously reported the ability of the pectin CHQ matrix patch to achieve a 
sustained, controlled release of CHQ (Musabayane et al., 2003c).. The ability of CHQ to avidly 
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bind to all epithelial cells of the body has been suggested to be responsible for the adverse effects 
of oral CHQ on various organ systems. The shortfall, however, is that only a single dose of 
pectin CHQ matrix patch was used. The high plasma CHQ concentrations were sustained until 
day 21 suggesting that the dose used in the patch was high. There may be a need to evaluate the 
effect of lower doses.   
 
6.3 Effects of CHQ treatments on: 
6.3.1 Parasitaemia 
Oral CHQ treatment, given twice daily, 8 hours apart for 5 continuous days and a once off 
topical application of CHQ, cleared the malaria parasites from systemic circulation during the 
treatment period. Considering that the CHQ patch was applied once, the results of the current 
study give evidence of sustained, controlled release of CHQ from our transdermal formulation 
that were able to clear the malaria parasites from systemic circulation within 3 days of treatment. 
Indeed, this may be a feasible alternative to conventional oral CHQ delivery of CHQ for the 
treatment of malaria.  
6.3.2 Blood glucose and plasma insulin 
P. berghei infection showed blood glucose lowering effects. Oral CHQ treatment exacerbated the 
blood glucose lowering effects of malaria infection. Treatment with pectin CHQ matrix patch did 
not alter the blood glucose concentrations of the animals throughout the 21 day experimental 
period. Oral CHQ treatment increased plasma insulin concentration and decreased blood glucose 
concentration, which were not altered by topical application of the pectin CHQ matrix patch in 
non infected animals. The blood glucose lowering effects of the patch acutely during the OGT 
responses demonstrates the sustained controlled release of CHQ from the transdermal 
formulation. However, the magnitude of the decline of blood glucose concentrations following 
patch treatment was lower, by comparison to oral treatment, suggestive of the adverse effects of 
oral CHQ delivery. The blood glucose lowering effects of the various doses of both oral CHQ 
treated and pectin CHQ matrix patch treated separate groups of animals were not significantly 
different from each other suggestive of a non dose dependant effect. The transdermal patch, just 
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like oral CHQ has demonstrated the ability to ensure rapid onset of action, when used as an 
adjunct to treat malaria 
 
Indeed other investigators have reported blood glucose lowering effects of the malaria parasites. 
Phillips (1989) reported that the parasite heavily and completely depends on the host for all its 
energy requirements, which impact negatively on the host’s energy store (Phillips 1989). The 
author went further to suggest that the overall effect may be an imbalance between the host’s 
energy demands and supply which may precipitate hypoglycaemia in patients with glucose-
insulin mismatching (Phillips 1989). Krishna et al, (1999), has previously reported that there are 
various mechanisms, which are currently still unclear, through which the malaria parasites may 
precipitate hypoglycaemia in the host. One such proposed mechanism is mediated through 
depletion of vital gluconeogenic substrates such as thiamine (Krishna et al., 1999). Dekker et al, 
(1996) concluded that the major determinant of plasma blood glucose of children with 
uncomplicated falciparum malaria is endogenous glucose productions as opposed to peripheral 
uptake as previously reported in adults (Dekker et al., 1996, Dekker et al., 1997). The author 
reported that gluconeogenesis is vital in the maintenance of blood glucose concentration in 
children with uncomplicated falciparum malaria (Dekker et al., 1996). Hypoglycaemia, which is 
caused by inhibition of glucose production and stimulation of glucose disposal, may therefore be 
more severe in children and pregnant women (Dekker et al., 1996). The hypoglycaemia in 
malaria patients may be attributed to low levels of gluconeogenic substrates, imbalance in the 
levels of hormones that maintain glucose homeostasis as well as high levels of cytokines, which 
is characteristic of malaria (Dekker et al., 1996).  
 
Blood glucose production in humans can be stimulated by catecholamines, glucagon and low 
levels of cytokines TNF-a and IL-6. Low levels of IL-l have reportedly been shown to induce 
hypoglycaemia in animals (Dekker et al., 1996, Dekker et al., 1997). The direct contribution of 
the malaria parasite in causing hypoglycaemia has only been reported to be less than 10%, as the 
authors suggested that the parasite only consumes at most 10% of the total blood glucose 
produced by the host, indicating that other factors such as metabolic  changes in the host are the 
most vital determinants of malaria induced hypoglycaemia (Dekker et al., 1996). In the current 
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study, weanling rats were used, which could also be an important factor in glucose homeostasis 
in a malaria model as previous studies by Dekker et al, (1996) indicated that glucose metabolism 
in falciparum malaria is differently regulated in children and adults (Dekker et al., 1996). The 
pathophysiology of hypoglycaemia in malaria remains unclear to date (English et al., 1998, 
Thien et al., 2006).  Dekker et al, (1997) has also attributed malaria induced hypoglycaemia  to 
liver damage associated with malaria . The liver damage results from the rapid proliferation and 
migration of malaria parasites from one hepatocyte to another during the life cycle of the malaria 
parasite has been shown to cause hepatocellular damage (Dekker et al., 1997). The liver is a key 
organ involved in the maintenance glucose homeostasis; hence any hepatocellular damage may 
impair glucose homeostasis. The liver plays a major role in breaking down the activated insulin-
receptor complex hence hepatocellular damage may, therefore, result in slow insulin receptor 
recycling, thereby precipitating overt hypoglycaemia in malaria (Onyesom and Agho, 2011). The 
results of the current study are therefore consistent with the findings of other scholars who have 
reported blood glucose lowering effects of the malaria parasites. 
 
On the other hand, besides the independent, malaria induced blood glucose lowering effects; 
findings of the current study indicate that CHQ also independently has blood glucose lowering 
effects. Indeed, this is in agreement with previous studies which have suggested that CHQ may 
possess hypoglycaemic properties. As already alluded to in section 1.4.2, various studies have 
suggested that CHQ may evoke hypoglycaemia through varied and unclear mechanisms 
(Knutson, Ronnett and Lane, 1985; Davis, 1997; Jarzyna, Kiersztan, Lisowa and Bryla, 2001). 
The suggested CHQ- induced hypoglycaemia has been ascribed to decreased insulin degradation 
(Knutson, Ronnett and Lane, 1985) or increased insulin secretion (Davis, 1997). Bevan et al, 
1995, has reported that hypoglycaemia may be due to CHQ induced extension of the life span of 
CHQ-insulin activated complex (Bevan et al., 1995). CHQ, being a diprotic base, rapidly 
accumulates in acidic lysosomes and endosomes thereby elevating lysosomal pH. An elevation 
of lysosomal pH compromises the optimal activity of lysosomal hydrolases that degrade hepatic 
insulin, with a concomitant increase in plasma concentration of intact insulin (Knuston, Ronnet 
and Lane, 1985). Smith et al, 1987, has also reported that non insulin dependent diabetic patients 
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that were given CHQ, had increased plasma insulin concentration with a concomitant 
improvement in their glucose tolerance (Smith et al., 1987). CHQ has also been shown to 
increase insulin secretion via rapid accumulation in the pancreas, thereby having a direct effect 
on the beta cells of islets of Langerhans (Asamoah et al., 1990). The CHQ evoked 
hypoglycaemia and elevations in urinary potassium output, as well as plasma potassium 
observed in the current study may also be partly attributed to the fact that in the pancreatic β -
cells glucose produces ATP by glycolysis. The resultant increased ATP, inhibits the K+-ATP 
channel, preventing K+ outflow which causes depolarization of the membrane (Ashcroft, 2007). 
Opening of voltage sensitive calcium channels follows membrane depolarization, with a 
consequent increase in intracellular calcium which leads to insulin secretion (Ashcroft, 2007) 
 
CHQ induced hypoglycaemia has also been ascribed to inhibition of gluconeogenesis due to 
CHQ induced hepatocellular damage (Jarzyna, Kiersztan, Lisowa and Bryla, 2001). CHQ 
induced hepatocellular damage may lead to inhibition of key gluconeogenic enzymes; glutamate 
dehydrogenase and glucose-6-phosphatase (Jarzyna et al., 2001). It may also lead to decreased 
transport of pyruvate into hepatocyte mitochondria (Jarzyna et al., 2001) with a concomitant 
decrease of gluconeogenesis, which may eventually cause hypoglycaemia. The results of the 
current study indicate that oral CHQ delivery decrease glucose homeostasis. However, the 
findings of the current study did not elucidate the mechanism of both malaria and CHQ induced 
hypoglycaemia. The blood glucose concentrations of the animals treated with pectin CHQ matrix 
patch remained stable throughout the 21 day experimental period. This suggests that the 
sustained controlled release of CHQ did not have adverse effects on blood glucose homeostasis. 
The controlled and sustained release of CHQ from our transdermal formulation, therefore, 
averted the challenges of dose dumping associated with oral CHQ delivery. We have for the first 
time shown that the CHQ concentrations released from the pectin matrix patch may circumvent 
the adverse effects of oral CHQ in the rat. 
The elevated blood glucose concentration of separate group of animals that were treated with 
transdermally delivered CHQ at the end of the experimental period could be attributed to 
increased food intake of the growing weanling rats. The other factor that may contribute to 
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decreased blood glucose concentration in orally treated animals is associated with the bitter taste 
of CHQ. The drug is unpalatable, thereby reducing the appetite of the animals. Transdermal 
delivery of CHQ masks the bitter taste of the drug; hence the feeding patterns of these animals 
did not change throughout the experimental period. We suggest that transdermal delivery of 
CHQ may, therefore, promote the completion of courses of therapy by malaria patients thereby 
reducing development of falciparum resistance to the drug. 
 
There is currently no literature evidence showing the effects of oral CHQ and transdermal 
delivery on hepatic and muscle glycogen storage. This is despite the pivotal role played by the 
liver in blood glucose homeostasis. Glycogen determination was performed using a protocol that 
has been used extensively in our laboratory (Ngubane et al., 2011) 
 
Hepatic glycogen concentration in non infected animals that were treated with oral CHQ was 
elevated in the current study. Indeed, we had speculated that since CHQ alters blood glucose and 
plasma insulin concentrations, it could be altering the hepatic and muscle glycogen stores as 
well. The hepatic glycogen concentrations of animals that were treated with transdermal patch 
remained stable throughout the 21 day study. The gastrocnemius muscle glycogen concentration 
of all the groups of animals remained stable throughout the experimental period. Elevations of 
plasma insulin and decreased blood glucose observed in this study could be partly responsible for 
increased hepatic glycogen concentrations. Insulin acts on insulin sensitive tissues such as the 
skeletal muscle, thereby promoting increased blood glucose uptake and eventually increased 
glycogen stores (Azpiazu et al., 2000). We, therefore, speculate that the increased plasma insulin 
concentrations following oral CHQ administration promoted glucose uptake in the muscle via the 
GLUT 4 transporters (Azpiazu et al., 2000, Ferrer et al., 2003). Possible increases in  glucose 
uptake by the liver via GLUT 2 transporters that are insulin independent could have led to 
increased glycogen stores in the organ (Agius, 2008). The mechanism through which the 
elevation of hepatic glycogen is mediated was not established in this study. We, however, 
speculate based on our previous findings that this could be due to the effects of CHQ on 
glycogenic enzymes, glucokinase and hexokinase (Ngubane et al., 2011). Previous studies have 
shown that falciparum malaria causes muscle damage, which could have masked the effects of 
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CHQ on glycogen concentration in this organ for the malaria infected animals (Davis et al., 
1999). The liver masses of the infected control animals and the oral CHQ treated infected 
animals were increased by comparison to non infected control animals the pectin CHQ matrix 
patch treated animals. This observation was consistent with  previously reported CHQ induced 
hepatocellular damage (Cooper and Magwere, 2008). This observation indicates the toxic effects 
of oral CHQ that may be circumvented by slowly released, in a controlled manner of CHQ from 
our transdermal formulation.  
108 
 
6.4 Renal function 
Renal function parameters were monitored every 3rd  day during the pre and post treatment 
periods and daily during the treatment period in separate groups of non infected and infected 
animals treated with oral CHQ and pectin CHQ matrix patch in a 21 day experimental study.  
 
6.4.1 Physico metabolic parameters 
 
As already mentioned above, malaria infection and oral CHQ treatment reduced food and water 
intake as well as decreasing % body weight changes.  The food intake, water intake and % body 
weight changes of non infected animals that were treated with pectin CHQ matrix patch 
remained stable throughout the experimental period, suggesting the ability of the transdermal 
formulation to circumvent the adverse effects of oral CHQ on these parameters. The reduction in 
food intake of oral CHQ treated animals is consistent with previous, attributing the reduced 
appetite to the nausea and bitter taste of CHQ (Tulpule and Krishnaswamy, 1982; Musabayane et 
al., 2003b). The unpalatability of CHQ possibly led to reduced body weight changes in this 
group of animals. When there is reduced feeding, the body may start to use other less easily 
accessible substrates such as fatty acids and amino acids as opposed to glucose, which may result 
in the observed reduction in body weight changes of the oral CHQ group (Table 2). This same 
phenomenon as previously mentioned may be partly responsible for the blood glucose lowering 
effects of oral CHQ 
 
6.4.2 Renal fluid and electrolyte handling and plasma biochemical parameters 
 
Infected animals had a significantly lower mean 24 hour urine output by comparison to non 
infected control animals. This finding agrees with reports by Das (2008) that malaria the 
pathogenesis of falciparum malaria leads to varying degrees of fluid and electrolyte imbalances 
characterized by extracellular fluid volume depletion (Boonpucknavig and Sitprija, 1979; Weller 
et al., 1992; English et al., 1996; Prakash et al., 1996; Prakash et al., 2002; Naqvi et al., 2003;  
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Das, 2008; Ogbadoyi and Tsado, 2009; Idonije et al., 2011). The mechanism leading to reduced 
urine output in malaria infected rats remain to be elucidated. The current study did not elucidate 
the mechanism.  
 
The results of the current study have also shown elevation of mean urinary Na+ outputs in non 
infected and infected animals treated with oral CHQ. These findings are consistent with previous 
observations that acutely administered oral CHQ stimulated AVP secretion (Musabayane et al., 
2000c) We have previously shown that acute CHQ treatment causes natriuresis, without 
affecting urine output (Musabayane et al., 1993, Musabayane et al., 1996) CHQ reportedly 
inhibits AVP induced cyclic adenosine monophosphate (cAMP) production at the level of the 
hormone receptor complex (Musabayane et al., 2000c.) CHQ therefore, reduces the 
concentration of cAMP in the inner medullary collecting ducts, thereby inhibiting the antidiuretic 
action of the hormone (Musabayane et al., 2000c). We have previously suggested the natriuretic 
effects of CHQ to be mediated via AVP effects on V1 receptors. On these receptors, AVP has 
pressor effects, thereby causing natriuresis without affecting urine flow rate  (Musabayane et al., 
2000b).  
Similarly, malaria infection may induce natriuresis through a similar mechanism leading to 
production of hyperosmotic urine (Elsheikha and Sheashaa, 2007, Ehrich and Eke, 2007, Das, 
2008). The mechanism of CHQ induced natriuresis was not elucidated in the current study, as the 
plasma AVP concentrations were not measured. 
 
The current study has also shown hyperkalaemia and elevated urinary K+ outputs in malaria 
infected control animals. .Elevated urinary K+ outputs were also shown in P berghei infected 
animals treated with oral CHQ. Malaria infection is associated with haemolysis of RBC, which 
may release cellular K+ into systemic circulation (Clark and Cowden, 2003; Das, 2008). The 
observed kaliuresis can, therefore be attributed to the increased filtered load of K+ Topical 
application of pectin CHQ matrix patch did not alter the urinary Na+ and K+ outputs of both non 
infected and infected animals, suggestive of the ability of the patch to circumvent the adverse 




Urinary creatinine outputs were elevated in P berghei infected animals treated with with oral 
CHQ. This observation is consistent with previous reports that falciparum malaria may impair 
renal fluid and electrolyte handling (Ekeanyanwu and Ogu, 2010). In the current study, there 
were no significant differences in GFR of the different experimental groups. GFR is a marker 
used to assess renal function (Narayanan and Appleton 1980; Smith et al 2006). Creatinine 
clearance (Cc) is used to estimate GFR (Narayanan and Appleton 1980; Smith et al 2006). It is 
speculated that other mechanisms could be influencing the observed impairments of renal fluid 
and electrolyte handling observed in the current study.  
 
All the experimental groups had stable 24 hour urinary urea outputs throughout the experimental 
period. Blood urea concentrations may not accurately be used to assess renal function because 
urea production may be altered by other factors such as dehydration, food intake, and tissue 




6.5 Cardiovascular function 
 
6.5.1 Haematocrit 
Reduction in the haematocrit of malaria infected animals by comparison to non infected group of 
animals is consistent with previous studies that have reported malaria induced anaemia 
(Menendez 2000). Indeed, anaemia is a common manifestation of malaria infection, which may 
indirectly influence haematocrit. Anaemia may result from pathophysiological mechanisms that 
promote increased destruction of infected RBCs through multiple mechanisms (Bjorkman, 2002; 
Clark and Cowden 2003). Decreased production of RBC associated with malaria infection may 
also lead to development of anaemia via varied mechanisms (Yap and Stevenson, 1994; El 
Hassan et al., 1997; Dondorp et al., 1999; Chang et al., 2004; Fendel et al., 2010). Oral CHQ 
treatment reduced haematocrit of both malaria infected and non infected animals. The 
observation is consistent with the previous reports suggesting quinoline drugs to act as haptens. 
CHQ may possibly bind to infected RBC proteins and become antigenic, eventually causing 
destruction of RBC, which may result in the development of anaemia (Clark and Cowden, 2003).  
Topical application of pectin CHQ matrix patch did not alter haematocrit of non infected 
animals, suggestive of the ability of the patch to circumvent the toxic effects of oral CHQ 
delivery 
The current study did not elucidate the mechanisms through which haematocrit was reduced in 
the infected and oral CHQ treated animals. Measurement of plasma cytokines may give a clear 
mechanism of the observed malaria induced haematocrit changes. 
 
6.5.2 Hypotensive effects of CHQ 
The results of the present study have demonstrated the hypotensive effects of malaria infection 
which were exacerbated by oral CHQ treatment. To date, the mechanisms responsible for 
orthostatic hypotension in malaria remain incompletely understood (Ekue et al., 1987).  Malaria 
induced hypotension may be mediated through development of bradycardia and redistribution of 
blood volume to the skin by peripheral vasodilatation (Ekue et al., 1987; Supanaranond et al., 
1993; Bethel et al 1996). Indeed, P.falciparum infection is generally associated with 
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hyperpyrexia and vasodilatation of peripheral blood vessels (Supanaranond et al., 1993; Bethel et 
al 1996).  
 
Hypotension associated with CHQ may be  a result of arteriolar dilatation and venodilatation 
(Anigbogun et al., 1993). CHQ induced venodilation, mediated via the release of NO in human 
forearm veins has been reported ((Abiose et al, 1997). Other mechanisms that have been 
suggested to explain the previously reported CHQ induced hypotensive effects, were CHQ 
ability to cause blockade of alpha receptors and increased histamine secretion (Abiose et al, 
1997). Mubagwa and Adler, 1998 have previously reported that CHQ may be invoking its 
actions via the muscarinic receptors (Mubagwa and Adler, 1988). The findings of this study 
have, therefore, demonstrated that malaria infection and oral CHQ delivery independently evoke 
hypotensive effects. The effects of transdermal delivery of CHQ on MAP were not measured in 
the current study.  
 
6.5.3 Lipid profile parameters 
 
Malaria infection and oral CHQ administration resulted in elevated plasma total cholesterol, 
LDL-c and reduction of plasma HDL-c. Reduction of the cardio protective particle, HDL-c may 
be a predisposing factor to premature coronary artery disease (Grundy, 1995). Reduced 
concentrations of plasma HDL-c may, therefore, be associated with development of 
atherosclerosis, which eventually lead to the development of CVD. HDL-c molecule has been 
shown to exert cardio protection through multiple mechanisms (Grundy, 1995; Libby, 2001; 
Toth, 2005; Natarajan et al., 2010). HDL has the ability to initiate reverse cholesterol transport, 
by removing and transporting cholesterol from cells to the liver for excretion (Grundy, 1995; 
Libby, 2001; Toth, 2005; Natarajan et al., 2010). .HDL is able to reduce the amount of 
cholesterol from the arterial walls, thereby slowing down the progression of atherosclerotic 
lesions (Grundy, 1995; Libby, 2001; Toth, 2005; Natarajan et al., 2010). HDL may mediate 
cardio protection by preventing the aggregation of LDL particles within the arterial wall or 
preventing the oxidation of LDL (Libby, 2001). Reduction of plasma HDL-c concentration may 




Elevated plasma total cholesterol and LDL-c particles is associated with atherogenesis, which 
may be a predisposing factor to development of atherosclerotic plagues (Grundy, 1995; Ross, 
1999). The findings of the current study suggest the need to monitor cardiovascular function in 
malaria patients taking CHQ. The effects of transdermal delivery of CHQ on lipid profile 






The results of the current study show for the first time that controlled, sustained release of 
therapeutic doses of CHQ, were delivered into systemic circulation following a once off topical 
application of pectin CHQ matrix patch. The delivered CHQ doses were able to clear malaria 
parasites from systemic circulation. 
The current study was able to distinguish between the pathophysiological effects of malaria and 
CHQ treatments on blood glucose and plasma insulin concentration. The study has demonstrated 
the independent blood glucose lowering effects of malaria infection and oral CHQ delivery 
which were circumvented by topical application of the pectin CHQ matrix patch. The study has 
also demonstrated that oral CHQ elevates hepatic glycogen storage through mechanisms that are 
still to be elucidated. Topical application of CHQ via pectin matrix patch did not alter hepatic 
and gastrocnemius muscle glycogen stores.  
 
The current study has demonstrated the independent ability of both malaria infection and oral 
CHQ to impair physico metabolic parameters and renal fluid electrolyte handling. Both malaria 
infection and oral CHQ delivery induced natriuresis, reduced urine output and increased urinary 
creatinine outputs. Malaria infection was shown to cause both hyperkalaemia and kaliuresis in 
experimental animals. 
 
The study has also demonstrated the hypotensive effects of malaria infection and oral CHQ 
delivery. Additionally, the results of the current study have also demonstrated the independent 
elevations of atherogenic particles, plasma total cholesterol and LDL-c as well as reduction in 
the cardioprotective particle, plasma HDL-c, due to malaria infection and oral CHQ delivery. 
 
Overall, the once off application of the CHQ patch was able to circumvent the adverse effects of 







The limitations and shortfalls of the current study included the use of a single dose was used in 
the short term studies to investigate and distinguish the pathophysiological effects of CHQ on 
glucose homeostasis, renal function and cardiovascular function. Inability to measure plasma 
AVP, cytokines, hs-CRP as well as hepatic and gastrocnemius muscle glycogenic enzymes 
hexokinase and glucokinase was a shortfall in the current study. Measurement of these 
parameters may help to elucidate the mechanisms for some of the findings of the current study. 
Another shortfall of the study was lack of histochemical analysis of the harvested organs yet; 
such analysis may give more information, pertaining to the possible adverse effects of oral CHQ 
treatment on the organ systems 
 
6.8 Future work and recommendations  
The future direction from the current study would be the use of various doses of CHQ in the 
pectin CHQ matrix patch, which may be useful in optimizing the transdermal formulation. 
Measurement of AVP may help in elucidating the exact mechanisms for the observed reduction 
in urine output and natriuresis in malaria infected animals treated with CHQ. Future work could 
also include measurement of plasma cytokines, which may give clearer mechanisms to explain 
the observed differences in haematocrit. The mechanisms responsible for the elevated hepatic 
glycogen concentrations were not established in the present study. We speculated that 
measurement of glycogenic enzymes hexokinase and glucokinase could give a possible 
explanation. Histochemical analysis of the harvested organs may also give more information, 
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a b s t r a c t
Artemisinin combination therapies have decreased malaria associated morbidity and mortality in several
parts of the world. On the other hand, malaria cases have increased in sub-Saharan Africa largely due to
falciparum resistance to the most frequently used drugs (chloroquine and sulphadoxine/pyrimethamine
(SP) combination). Therapeutic failure has also been attributed in part to adverse effects of anti-malarial
drugs and patients’ non-compliance due to inconvenient dosing schedules. We consider that formulation
and evaluation of novel drug delivery systems is not only less expensive than developing new drugs, but
may also improve delivery of anti-malarials at the desired rates. In this review we evaluate the therapeutic
efficacy of existing anti-malarial drugs and assess the feasibility of developing novel formulations and
delivery systems.
© 2011 Elsevier B.V. All rights reserved.
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1. Introduction
The elimination of malaria is now considered a realistic goal
because of good surveillance and high intervention coverage
between 2000 and 2007 which resulted in the reduction of malaria
cases and deaths by 50% or more in some countries and regions
of African countries (WHO, 2008). Against this background, how-
ever, are reports that each year 300-500 million people suffer from
acute malaria, and 0.5-2.5 million die of the disease of which 90%
are in sub-Saharan Africa (WHO, 2008). Early treatment with effec-
tive anti-malarial drugs is the main life-saving intervention but,
treatment is threatened by intensification of the growing resistance
of P. falciparum to drugs that were once effective posing tremen-
dous challenges to malaria control. Indeed, the therapeutic life
of widely used anti-malarial drugs, sulphadoxine–pyrimethamine
(SP) and amodiaquine also appears to be limited due to an increase
in parasite resistance around the world. Given the widespread
resistance to available drugs, there is broad consensus to search
for effective, safe and affordable new anti-malarial drugs. In this
review we focus on the therapeutic efficacy of existing anti-malarial
drugs, examine the potential of novel formulation delivery sys-
tems of anti-malarial drugs and identify challenges required to
optimize malaria therapy. Traditionally, enhancing drug therapy
has involved seeking of new chemical entities or incorporation of
existing drugs into novel drug delivery systems. It is our view that
research should focus on the reformulation of current anti-malarial
therapeutic agents for novel delivery routes while developing new
drugs.
2. Malaria chemotherapy
Effective malaria chemotherapy aims at treatment of the patient
combined with blocking the infectivity of the parasite to the vector
by exploiting the differences in metabolism between the Plasmod-
ium parasite and the host. Although repeated administration of
anti-malarial drugs at sub-therapeutic doses can interrupt par-
asite transmission, this mode of treatment has been associated
with development of drug resistance (Watkins and Masobo, 1993)
and is also apparently considered to be the reason for chloroquine
(CQ) resistance.
Four Plasmodium species, P. falciparum, P. vivax, P. malariae
and P. ovale cause malaria in humans. P. falciparum is the most
virulent human malaria parasite due to its rapid rate of repro-
duction and ability to sequester in small blood vessels (Duong
et al., 2004). P. vivax, P. ovale and P. malariae, rarely cause fatal ill-
ness, but P. knowlesi may cause death due to its explosive asexual
erythrocytic cycle (Cox-Singh et al., 2008). Knowledge of the Plas-
modium life cycle shown in Fig. 1 is essential for drug interventions
studies.
Malaria parasites (sporozoites) inoculated by the female
Anopheles mosquito (vector) into the vertebrate host blood
stream infect the liver cells and mature asexually into merozoites
(exoerythrocytic schizogony). The merozoites issuing from the
pre-erythrocytic schizogony infect the erythrocytes in blood where
merozoites are produced (erythrocytic phase) which differentiate
into gametocytes. The erythrocytic phase is responsible for the
clinical manifestation of malaria. Mature Plasmodium gametocytes
are more drug resistant and hence effective malaria treatment
should inhibit gametocytogenesis to avert transmission. Drugs
with gametocytocidal activity and CQ target this stage of the
life cycle. Therefore, artemisinins, primaquine (PQ) and other
8-aminoquinolines amplify the impact of other interventions by
inhibiting the sexual stages of Plasmodium. The goal of the malaria
chemotherapy is to find a drug that has both anti-recrudescence
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Fig. 1. Illustration of the life cycle of malaria parasites of Plasmodium spp.
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Table 1
Malaria chemotherapeutic agents.
Drug Mode of action Limitations
QN related Disrupts parasite membrane function resulting in cell lysis




QN Monoprotic weak base with both blood schizontocidal and
gametocytocidal activity
Cardiotoxicity, hypoglycaemic (Ferreras et al., 2007;
Alkadi, 2007)
Mefloquine Diprotic weak base with both blood schizontocidal and
gametocytocidal activity
Gastrointestinal disturbances (GI), neuropsychiatry
disorders (Alkadi, 2007)
9-Aminoquinolines
CQ Blood schizontocidal and gametocytocidal activity via
inhibition of the degradation of haeme (which is toxic to
the malaria parasite),
Cardiotoxicity, impaired renal function, ocular toxicity
(Siqueira-Batista et al., 1998; Alkadi, 2007)
Amodiaquine Similar to CQ has both blood schizontocidal and
gametocytocidal activity
Peripheral neuropathy and haemolytic anaemia (Tafazoli
and O’Brien, 2009; Akpalu et al., 2005)
4-Aminoquinoline
Primaquine Blood schizontocidal and gametocytocidal activity via
inhibition of protein transport
Adverse effects include anaemia and GI disturbances
(Shekalaghe et al., 2010; Shanks et al., 2001).
Lumefantrine Blood schizontocidal and gametocytocidal activities;
interferes with detoxifying pathway for the malaria
parasite.
No major side effect, except the occurrence of mouth
ulcers in some patients (Assefa et al., 2010)
Halofantrine Mode of action unclear Cardiaovascular disorders, nausea, vomiting, anorexia and
diarrhoea (Olliaro and Bloland, 2001)





Blood schizontocidal and gametocytocidal activities Mental depression, gastrointestinal disorders (Alkadi,
2007)
Proguanil Dehydrofolate reductase inhibitor with blood
schizontocidal and gametocytocidal activity
Dizziness and nausea, acute megaloblastic anaemia (Sirsat
and Dasgupta, 1997)
Artemisinin derivatives Generate free radicals which cause haemolysis and lysis of
infected cells
Artesunate Blood schizonticide, reduces gametocyte carriage rate Ataxia, neurotoxicity, decreases reticulocytes, white blood
cells and haemoglobin concentration (Kongpatanakul
et al., 2009)
Artemether Blood schizontocidal and gametocytocidal activities Bradycardia, atrio-ventricular block Rare bradycardia,
atrio-ventricular block (Alkadi, 2007)
Plasmodium species exhibit a similar life cycle with only minor
variations. For instance a proportion of a form of parasites, hyp-
nozoites from P. vivax and P. ovale remains dormant in the liver
cells before undergoing asexual replication. Relapse can occur any
time after the primary attack due to re-activation of a hypnozoites.
Whereas relapse usually occurs within the first two or three months
of the primary attack malaria due to re-activation of a hypnozoites,
there are reports that P. vivax hypnozoites can produce clinical
infection 1–3 years after the original attack (Garnham et al., 1975;
Adak et al., 1998). It should be noted that the therapeutic efficacy of
the drugs is limited by factors which include falciparum resistance
and toxicity (Saussine et al., 2009). A list of some of the currently
used anti-malarial drugs given in Table 1 is briefly discussed in the
following sections.
3. Artemisinin derivatives
Derivatives of Artemisia annua L. (Qinghao, Asteraceae) are con-
sidered the cornerstone of the treatment of falciparum malaria
due to their potency and rapid action (WHO, 2006). Indeed,
the introduction of artemisinin-based combination therapy (ACT)
interventions decreased morbidity and mortality associated with
malaria in several parts of the world (Ogbonna and Uneke, 2008).
ACTs in common use include artemether-lumifantrine (Coartem),
artesunate-mefloquine and artesunate-amodiaquine. Artemisinin
based regimen possess gametocytocidal properties by inhibit-
ing parasite transmission to probably reduce the development
of anti-malarial resistance (Nosten and White, 2007). The WHO
Expert Consultative Group recommended artemisinin combina-
tion therapy (ACT) to combat falciparum resistance based on these
properties. Major limitations of ACTs have been ascribed to the
imbalance between demand and supply, comparatively high cost,
dosing complexity and the lack of clinical experience (Bloland,
2003). Reports of high failure rates associated with ACT therapy
along the Thai–Cambodian border (Vijaykadga et al., 2006; Noedl
et al., 2008) as well as in vitro drug-susceptibility data (Jambou et al.,
2005) suggest the possibility of clinical artemisinin resistance. In
addition, high doses of artemisinin derivatives have been reported
to elicit dose-, time- and route-dependent central nervous system
toxicity in laboratory animals (Petras et al., 2000). Interestingly,
no serious side effects due to artemisinin derivatives have been
reported in human studies to date. We suggest that the discrep-
ancy between animal and human studies can partly be attributed
to different routes of administrations.
4. Quinine (QN) related drugs
4.1. Quinine (QN)
Quinine (QN) derived from shrubs of various species of Rubia-
ceous genera, Cinchona and Remijia was the first successful use
of a chemical against malaria. QN, a blood schizonticide is also
active against the asexual erythrocytic forms of P. falciparum, P.
malariae, P. ovale and P. vivax. In addition, QN is gametocytocidal
for P. malariae and P. vivax but, has no direct activity against the
gametocytes of P. falciparum. Although resistance to QN is rare,
cases have been reported. QN salts may be given orally or intra-
venously (IV), intramuscularly (IM) or rectally (PR) (Barennes et al.,
2006). The intravenous administration is the preferred route for
severe falciparum malaria achieving peak plasma concentrations
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in 1–3 h. Thus QN should be diluted and infused slowly. A loading
dose (usually 20 mg kg−1 body weight) is given over 4 h followed by
maintenance infusions (10 mg kg−1, infused over 2 h every 8–12 h)
(Warrell et al., 1990). Moderately elevated QN is associated with
several features termed cinchonism (auditory symptoms, gastroin-
testinal disturbances, vasodilation, headache, nausea and blurred
vision) (Taylor and White, 2004), hypoglycaemia (Dyson et al.,
1985), haemolytic–uraemic syndrome (Gottschall. et al., 1991), and
thrombocytopaenia (Glynne et al., 1999). These adverse effects are
considered to be the root cause of poor compliance to QN. Clinically,
QN toxicity is observed in self-poisoning like the use of excessive
QN in the hope of achieving abortion.
4.2. Chloroquine (CQ)
CQ is a rapid acting schizontocide against P. falciparum with
gametocytocidal activity against asexual erythrocytic forms of P.
malariae, P. ovale and P. vivax. CQ remains the most frequently
used drug option for falciparum malaria in sub-Saharan Africa
countries (Winstanley et al., 2004) despite the emergence resis-
tant parasites. Consequently, CQ can no longer be considered an
adequately effective therapy of P. falciparum in these areas of
Africa. Of note, several east African countries have replaced CQ
with sulphadoxine–pyrimethamine (SP, Fansidar). To rescue the
therapeutic efficacy of CQ, approaches undertaken include the
development of amodiaquine following structural modifications of
the parent compound and linkage to a transition metal molecule to
produce ferroquine (Kreidenweiss et al., 2006).
CQ is slowly eliminated from the body and hence accumulates
in certain organs and tissues of the body such as the adrenal glands
and alters physiological function of the organs. Studies indicate
adverse CQ effects on kidney (Musabayane et al., 1996), cardiovas-
cular system (Siqueira-Batista et al., 1998) and the retina (Ferreras
et al., 2007).
4.3. Mefloquine
Mefloquine, a quinoline derivative structurally related to QN
is a blood schizontocide which inhibits the asexual stages of
P. falciparum and P. vivax, but has no effect on the hepatic
stage of malaria parasites. Resistance to mefloquine has been
reported leading to the use of combinations of mefloquine
with sulphadoxine/pyrimethamine (SP) or mefloquine/artemisinin
derivatives/combinations. Neuropsychiatric adverse events associ-
ated with mefloquine prophylaxis have been reported (Winstanley,
1996). In view of the long half-life of the drug, its administration in
areas with intensive malaria transmission is contra-indicated.
4.4. Primaquine (PQ)
The 8-aminoquinoline, PQ is a schizonticide used to eradicate
the pre-erythrocytic liver latent tissue forms of P. vivax and P. ovale
which cause malaria relapses. Whilst PQ remains the drug of choice
to eradicate and control hypnozoites of P. vivax and P. ovale P. vivax
the antimalarial may precipitate haemolytic anaemia in glucose-
6-phosphate dehydrogenase (G-6-PD) deficient patients (Burgoine
et al., 2010). Against this background is evidence suggests, however,
that a course of 8 weekly doses may be a safe and effective alterna-
tive to the traditional 14 day course of the drug (Myat-Phone-Kyaw
et al., 1994). In P. falciparum infection, a single dose of 0.75 mg/kg
is given against the gametocytes (excluding patients <4 years and
pregnant women) and is still superior to artemisinin derivatives.
This dose can also be tolerated by G6PD deficient patients. PQ also
eradicates the primary exoerythrocytic stage of Plasmodium species
as well as gametocytocidal and sporontocidal phases. PQ is orally
administered daily due to its short half life and high doses are
associated with haematological disorders and gastrointestinal dis-
turbances (Baird and Rieckmann, 2003). Transdermal PQ delivery
studies may overcome these shortfalls (Mayorga et al., 1998).
5. Anti-folates
The inhibition of falciparum folate metabolism remains an
attractive target for malaria treatment. Anti-folate derivatives
interfere with folate metabolism, a pathway essential for survival
of the parasite via inhibition of enzymes dihydrofolate reductase
(DDFR) (Bzik et al., 1987) and dihydropteroate synthase (DHPS)
(Lu et al., 2010). The combination of pyrimethamine, an inhitor of
DHFR, and sulphadoxine (SD) an inhibitor of DHPS, has been widely
used for the treatment of malaria, but due to the development of
resistance to DHPS and DFHR antagonists the activity has been lost
in most parts of the world including tropical Africa.
5.1. Sulphadoxine/pyrimethamine (SP) combination
SP drug combination is the most widely used option for uncom-
plicated P. falciparum malaria in several African countries because
it is affordable and practicable. SP combination has a long-life and
is, therefore, prone to the rapid emergence of resistance falciparum
parasites due to the slow elimination from the body (Nwanyanwu
et al., 1996; Mugittu et al., 2005). Pyrimethamine is also formulated
in fixed combination with sulpalene or dapsone.
5.2. Proguanil
Proguanil, a folate antagonist which destroys the malaria par-
asite by inhibiting DDFR is used for malaria prophylaxis in some
countries (Mulenga et al., 2006). However, clinical failure rates have
cast a shadow on the drug’s further development.
6. New anti-malarial drugs
Strategies in the discovery and development of new anti-
malarial drugs have ranged from minor modifications and
reformulation of existing drugs to designing agents that act against
new targets. Currently, several treatment options have been devel-
oped based on existing anti-malarial drugs in contrast with the
period when CQ monotherapy was the standard treatment. This
section briefly describes chemotherapeutic agents that have been
developed to improve malaria treatment.
6.1. Artemether/lumefantrine combination
Current WHO guidelines recommend the ACT
artemether/lumefantrine (AL) for the treatment of uncompli-
cated malaria caused by Plasmodium falciparum (WHO, 2008).
Artemether is a methyl-ether derivative of artemisinin with blood
schizontocidal and gametocytocidal activities while lumefantrine
is a racemic fluorine derivative with high blood schizontocidal
activity (Wernsdorfer et al., 1998). Artemether with a half-life
of 2–3 h is easily absorbed and rapidly eliminated from plasma,
whereas lumefantrine with a half-life of three to six days is
eliminated slowly and thus provides a high long-term cure rate.
Therefore, the complementary pharmacokinetics and dissimilar
modes of action of AL provides synergistic anti-malarial activity
and hence rapid clearance of parasitaemia after a short treatment
course. Studies have shown AL to be effective both in sub-Saharan
Africa and in areas with multi-drug resistant P. falciparum in
Southeast Asia (Hutagalung et al., 2005; Kokwaro et al., 2007;
Achan et al., 2009). It should be noted that AL combination is
active against the blood stages of P. vivax, but is not active against
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hypnozoites. Therefore, an 8-amino-quinoline derivative such as
PQ should be given sequentially after the combination in cases of
mixed infections of P. falciparum and P. vivax to achieve hypno-
zoites eradication. Several studies have confirmed the safety and
tolerability of AL in in a wide range of patient populations including
children (van Vugt et al., 1999; Falade et al., 2005; Abdulla et al.,
2008; Hatz et al., 2008).
6.2. Dihydroartemisinin (DHA) and piperaquine
Several studies indicate that the dihydroartemisinin (DHA) and
piperaquine (PQP) combination has the potential to be an effective
anti-malarial drug against multi-drug resistant falciparum malaria
(Giao et al., 2004; Ashley et al., 2004, 2005; Zwang et al., 2009).
The DHA/PQP combination rapidly reduces parasite biomass in the
patient through the brief yet potent activity of DHA and the sub-
sequent removal of uncleared parasites by the less active but more
slowly eliminated PQP (Tarning et al., 2005). DHA, an artemisinin
derivative, and PQP, a bisquinoline, have elimination half-lives of
approximately 1 h (Newton et al., 2000) and approximately 2–3
weeks (Hung et al., 2003, 2004), respectively. The two components
of DHA and PQP provide a combination that is relatively inexpen-
sive and has been shown to be effective both in curing malaria and
preventing re-infection (Zwang et al., 2009). DHA/PQP combina-
tion is well tolerated by all age groups. A major concern with the
DHA/PQP combination is that the long half-life of PQP will facilitate
the selection of drug resistant parasites.
7. Optimization of therapy
A combination of new as well as old anti-malarial agents has
been used as first-line therapy for malaria in Africa and other areas
with widespread Plasmodium drug resistance. The options include
amodiaquine/sulpadoxine/pyrimethamine (Ogungbamigbe et al.,
2008), atreminisin (Kublin et al., 2002), chlorproguanil/dapsone
(Fanello et al., 2008) and atovaquone/proguanil (Srivastava and
Vaidya, 1999).
7.1. Analogues of existing agents
Quinine analogues (CQ, PQ and mefloquine) were developed
through chemical strategies to improve on the chemother-
apeutic effect of the anti-malarial drug http://jeb.biologists.
org/cgi/content/full/206/21/3735-REF81. Analogues of 4-
aminoquinolines closely related to CQ such as PQ, a bisquinoline
have also been developed and appear to offer the anti-malarial
potency of the parent drug, even against CQ-resistant parasites
(Kaschula et al., 2002). Additionally, the toxicity of halofantrine, a
drug which has a structure closely related to QN has led to the devel-
opment of an analogue lumefantrine which is now a component
of the new combination co-artemether (artemether/lumefantrine)
(van Vugt et al., 2000). The same strategy has been applied leading
to the discovery of new artemisinins derivatives (endoperoxides)
(Posner et al., 2003) and folate antagonists (Tarnchompoo et al.
(2002).
7.2. Amodiaquine (AQ)/sulphadoxine/pyrimethamine (SP)
Amodiaquine (AQ) was widely used in various malaria endemic
areas until WHO withdrew its endorsement for malaria control pro-
gramme in 1990 as a result of reports of rare but severe toxic effects
(Olliaro et al., 1996). However, there is renewed interest in AQ as a
possible alternative to CQ, as it is effective even in areas of intense
CQ resistance and has a side-effect profile similar to that of CQ
and SP (Brasseur et al., 1999; Gorissen et al., 2000; Staedke et al.,
2001). Several studies indicate that AQ is effective in treating CQ-
resistant P. falciparum malaria parasites (Olliaro et al., 1996; Van
Dillen et al., 1999), despite the reported hematological side effects
(Phillips-Howard and West, 1990). Increasing P. falciparum resis-
tance to CQ in sub-Saharan Africa necessitates use of alternative
antimalarial agents. One alternative regimen, amodiaquine (AQ)
plus SP, has shown surprisingly good efficacy in Uganda (Staedke
et al., 2001; Dorsey et al., 2002; Gasasira et al., 2003). The SP/AQ
antimalarial combination which has shown surprisingly good effi-
cacy for treatment of uncomplicated malaria offers low-cost option
for in Africa.
7.3. Natural products
Extensive evaluation of naturally occurring products and medic-
inal plants has been reported for therapies of many human diseases.
Indeed, natural products are the sources of the two most impor-
tant drugs (QN and artemisinins derivatives) currently available to
treat severe falciparum malaria. Literature evidence indicates that
research approaches aimed at optimizing malaria chemotherapy
therapy include modifications of existing agents with natural prod-
ucts. Such drugs at the pre-clinical stages or currently undergoing
clinical trials have been reported in literature, but have not been
discussed as they are outside the scope of this review.
8. Novel anti-malarial drug delivery systems
The discussion in the in the preceding sections highlights the
possibility of developing of anti-malarial drugs and novel delivery
formulations that are envisaged to improve the efficacy, speci-
ficity, tolerability and therapeutic index of existing drugs. Such
formulations are likely to modify the traditional oral dosing sched-
ule of drugs such as CQ whose toxicity has been attributed to
transiently high plasma concentrations following oral adminis-
tration (Siqueira-Batista et al., 1998). Studies indicate successful
controlled release of CQ from the synthetic polymer, Eudragit RS
100 (Ndesendo et al., 1996) as well as from pectin (polygalac-
turonic acid) (Musabayane et al., 2003). Synthetic polymers are
disadvantaged by the use of organic solvents and hence relatively
harsh formulation conditions. These novel drug delivery systems
are likely to optimise the therapeutic efficacy of anti-malarials.
Novel drug delivery systems investigated to date include CQ-
pectin formulations (Musabayane et al., 2003) lipid nanoemulsion
or liposome-entrapping of PQ (Green et al., 2004). Biodegrad-
able natural polymers (albumin, gelatin, alginate, collagen and
chitosan) and synthetic polymers (lactide, glycolide, poly(lactide-
co-glycolide) (PLGA) have been used as drug delivery systems
although they have a relatively short duration of drug release
(Rytting et al., 2008).
8.1. Liposomes
Liposomes are lipid vesicles used extensively for controlled
delivery drug formulations. Liposome formulations inhibit rapid
clearance by controlling the size, charge, and surface hydration
of the drug. Studies show that liposomes are effective carriers of
anti-malarial drugs (Singh and Vingkar, 2008) as evidenced by that
they increase bioavailability of arteminisin derivatives (Gabriels
and Plaizier-Vercammen, 2003) to avert malaria recrudescence
in experimental animals (Chimanuka et al., 2002). Furthermore,
reports indicate sustained prolonged CQ release from liposome for-
mulations (Owais et al., 1995) and PQ (Dierling and Cui, 2005). In
addition, CQ- and PQ formulations targeting erythrocytes (Chandra,
2007) and the liver (Singh and Vingkar, 2008) have been developed.
Enhanced safety and efficacy have also been achieved for a wide
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Table 2
Transdermal formulations of malaria chemotherapeutic agents.
Drug Formulation Main findings References
Aminoquinolines
CQ CQ/pectin hydrogel matrix Sustained controlled CQ release Musabayane et al. (2003)
PQ PQ/- Eudragit® RL 100-, ethyl cellulose polymers with various
penetration enhancers (Mygliol® 840, Labrafac Hydrophile® ,
Transcutol® , propylene glycol, oleic acid, etc.)
Ethyl cellulose-based formulations with
Mygliol®840 achieved the high plasma PQ
Mayorga et al. (1996)
PQ/ethyl cellulose polymer mixed with Mygliol® 840
penetration enhancer plus the antioxidant alpha-tocopherol
Sustained controlled PQ release over 40 h Mayorga et al. (1997)
PQ/Starch with Mygliol® 840 as a penetration enhancer Controlled PQ release; with no enhancing effect. Jeans and Heard (1999)
PQ with Mygliol® 840 as a penetration enhancer Extensive binding of PQ to corneocyte keratin
which has a significant effect on reservoir
formation and permeability
Heard et al. (2003)
Artemisinin derivatives
Artelinic acid Artelinic acid/methyl cellulose with combined penetration
enhancers dimethyl phthalate/azone
Prophylaxis and rapid elimination of parasites in
experimental animals
Klayman et al. (1991)
Artemisinin, artemether,
dehydroartemisin
Artemisinin derivatives/ethyl cellulose with the penetration
enhancer dimethyl phthalate.
Prophylactic and curative effects in experimental
animals
Lin et al. (1994)
Antibiotics
Doxycycline Saturated solutions of doxycycline/Mygliol® 840 and ethanol Improved doxycycline transport across the skin Perkins and Heard (1999)
Triclosan Triclosan/acrylic polymer DuroTak® Improved triclosan transport across the skin Chedgzoy et al. (2002)
range of drug classes, including antitumor agents, antivirals, anti-
fungals, antimicrobials, vaccines and gene therapeutics (Sharma
and Sharma, 1997).
8.2. Nanoparticles
Polymeric nanoparticle devices are biocompatible, slowly
hydrolyzed polymer devices such as poly lactide gelatin, albu-
min, polyalcrylamide, polyisohexylcyanoacrylate and polydiethyl-
methylidene malonate that control delivery of drugs. Polymeric
nanoparticle devices have been used to deliver anti-malarial drugs,
halofantrine (Legrand et al., 2003), Artemisia annua derivatives
(Wan et al., 1992) and CQ (Agrawal et al., 2007) in experimen-
tal animals. An added advantage of nanoparticle delivery devices
is that they can passively deliver drugs to lysosomes of phago-
cytes of the mononuclear phagocyte system, following intravenous
administration (Rodrigues et al., 1994). The release of the drug
at the site following lysosomal degradation enhances the efficacy
of the active agent. Indeed, pharmacokinetic evaluation of the
albumin-encapsulated PQ targeted to the mouse liver showed sig-
nificantly higher concentrations of PQ in liver tissues relative to
free drug (Green et al., 2004). Gelatine nanoparticles or galactose-
coated drug dendrimers have also been studied for controlled PQ
delivery (Agrawal et al., 2007). Reports indicate that PQ loaded-
poly(d,l-lactide) nanoparticles were not only tolerated by healthy
and Leishmania donovani-infected mice, but also reduced the 50%
lethal dose when compared to the free PQ (Rodrigues et al., 1994).
8.3. Ceramic implants
Polymers (polylactic acid, gelatin or chitosan) are matrices for
ceramic particles that can introduce a tailored biodegradable drug.
Gelatine ceramic implants have been reported to sustain consis-
tent therapeutic blood CQ concentrations in experimental animals
(Saparia et al., 2001).
8.4. Microemulsions
Microemulsions drug delivery systems containing water, oil
and active agent have been used in pharmaceutical and medical
practice since the earliest days. Gum arabic (branched polysac-
charide) microemulsions have been developed for CQ (Vaziri and
Warburton, 1994) and PQ (Nishi and Jayakrishnan, 2004). The drug
covalently couples via imine bond to aldehyde groups generated
by oxidizing the polysaccharide with periodate and simultaneously
fabricates into microspheres. Other studies indicate sustained con-
trolled CQ release from ethyl cellulose microsphere (Patel et al.,
2006). A biodegradable polyphosphoester, poly[[(cholesteryl oxo-
carbonylamido ethyl) methyl bis(ethylene) ammonium iodide]
ethyl phosphate] (PCEP) micelle has also been reported to effi-
ciently deliver CQ in vitro (Wen et al., 2004).
8.5. Transdermal delivery
Transdermal delivery provides an alternative route of anti-
malarial drugs. The advantages of transdermal route include
avoidance of hepatic first-pass metabolism, easy administra-
tion and possibility of immediate withdrawal of the treatment.
Although, transdermal delivery is limited by low skin permeabil-
ity, methods such as active cationic liposomal delivery (Nair et al.,
2009) and electroporation techniques (Sen et al., 2002) developed
in the last decades enhance permeation. Indeed, we reported phys-
iological effects of CQ following topical application of pectin-CQ
hydrogel matrix patch on the rat skin using dimethyl sulphoxide
as a penetration enhancer (Musabayane et al., 2003). The obser-
vations suggest that the anti-malarial can be delivered through
the transdermal route. Sustained plasma concentration of PQ with
concomitant inhibitory activity on asexual malaria parasites has
also been reported in experimental animals following transdermal
PQ administration (Mayorga et al., 1997). This is beneficial con-
sidering that the prophylactic and therapeutic applications of PQ
are hampered by dose dependant adverse effects (Winstanley and
Breckenridge, 1987). Table 2 below gives an outline of transdermal
delivery studies conducted for anti-malarial drugs.
8.6. Rectal delivery
The rectal drug delivery route has been used to deliver
artemisinin formulations (Kuranajeewa et al., 2007) and QN
(Barennes et al., 1999) despite the observations that the route is
associated with marked inter individual variability and bioavail-
ability of the drugs (Kuranajeewa et al., 2007). The rate and extent
of rectal drug absorption are often low possibly due to the relatively
small surface area available for drug uptake. The composition of the
rectal formulation (solid vs liquid, nature of the suppository base)
appears to be an important factor determining the absorption pro-
cess and pattern of drug release (Yong et al., 2003). Barennes et al.
(1999), however, developed a rectally delivered QN cream formula-
tion with improved parasitological efficacy and pharmacokinetics
in children with P. falciparum malaria relative to intramuscular and
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intravenous injections. This has immense public health benefits
considering that intramuscular injection of QN has been associated
with complications that include injection paralysis (Barennes et al.,
1996) and limitations such as being unsuitable for field use or in
poorly equipped rural hospitals. Rectal administration is a painless
procedure that enables self administration, and reduces the risk of
infections from already used needles (Barennes et al., 1996).
8.7. Nasal delivery
The nasal drug delivery route is easily accessible and offers a
wide surface area for drug absorption (Illum, 2003). One particu-
lar advantage of the nasal route is the simplicity of administration,
allowing easy treatment following the first signs of illness. More-
over, the nasal cavity allows the drugs to be delivered directly to
the brain via the nasal membrane (Graff and Pollack, 2005) which is
vital in cerebral malaria. However, limitations of this route include
rapid removal of the drug from the site of deposition by mucocil-
iary clearance by enzymatic degradation, low permeability of the
nasal epithelium and erratic bio-availability (Galloway and Chance,
1994). Against this background are observations of effective Plas-
modium infection treatment in rodents with nasally administered
dihydroartemisinin formulations (Touitou et al., 2006).
9. Conclusions and future studies
We have briefly described the ways in which anti-malarial drug
regimens are employed and suggested delivery strategies to opti-
mize treatment. Evidence presented in this review indicates that
chemotherapy remains one of the main ways of controlling malaria,
although the sensitivity of falciparum malaria to CQ the main stay
therapy drug for malaria has rapidly declined throughout the trop-
ics. This review has briefly highlighted some of the current research
in the development of anti-malarial drug formulations. Irrespec-
tive of the methods used now, there is no doubt that further
research based on fundamental knowledge of existing drugs will
yield novel therapeutic strategies and formulation approaches that
may improve malaria chemotherapy.
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